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ABSTRACT 
Cardiovascular disease (CVD) is a major cause of morbidity and premature death in 
Sweden and globally, which besides the substantial individual suffering, puts large 
restraints on the public health system. Adiponectin is a highly heritable trait, which is 
strongly associated with metabolic disturbances such as obesity and insulin resistance. 
Previous studies indicate that adiponectin may play a fundamental role in the 
development of CVD. However, further knowledge about pathways linking circulating 
adiponectin, genetic loci, and markers of early CVD is needed. Therefore, the overall 
aim of this thesis was to assess the genetic determinants of adiponectin, and the role of 
adiponectin in the development of subclinical CVD. 
 
In Study I, we investigated the association between adiponectin and cardiac geometry 
and function in two cross-sectional samples of elderly and found that high adiponectin 
levels were associated with poorer cardiac function in men. This association was 
dependent on N-terminal pro-brain natriuretic peptide and this was more pronounced in 
individuals with prior CVD, which could indicate a counter-active effect in response to 
decreased cardiac function, potentially mediated by natriuretic peptides. 
 
In Study II, we examined the role of adiponectin in vascular pathology in a cross-
sectional study design where higher adiponectin levels were associated with a lower 
lipid-content in plaques and higher vessel wall elasticity, indicating less arterial 
pathology. 
 
In Study III, we assessed oxidative stress and inflammatory markers in relation to 
adiponectin, where adiponectin was positively associated with the anti-oxidant 
glutathione and inversely associated with lipid peroxidation as well as epidermal 
growth factor. Our findings suggest that adiponectin is associated with a more 
beneficial oxidative stress profile. 
 
In Study IV, we explored the impact of rare genetic loci on circulating adiponectin 
levels on a genome-wide scale. Besides several independent variants around the 
adiponectin gene, we found a rare coding variant in a gene upstream of adiponectin 
receptor 2 that was associated with higher adiponectin levels. If replicated in an 
independent sample, these findings can provide new insight to adiponectin biology.  
 
In conclusion, we found that individuals with poor cardiac function had higher levels of 
adiponectin and the results suggested that natriuretic peptides had an important role in a 
potentially counter-active mechanism. In contrast, high adiponectin levels were 
associated with a more beneficial arterial, oxidative stress and inflammation profile. 
Finally, rare variation around the adiponectin gene and a potentially novel locus 
upstream of the adiponectin receptor 2 gene was associated with adiponectin levels. 
 
Keywords: adiponectin, cardiovascular disease, oxidative stress, inflammation, rare 
genetic variation. 
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1 BACKGROUND 
1.1 Cardiovascular Disease and Adipose Tissue 
Cardiovascular disease (CVD) is the leading cause of death, accounting for one third of 
the total number of deaths in the world.1 The prevalence of CVD is increasing, e.g. by 
2030, 40.5% of all Americans are expected to have some form of CVD.2 In addition to 
substantial individual suffering, CVD puts a large burden on public health care with 
substantial costs that are expected to increase.2, 3 In the United States the direct medical 
costs of CVD are expected to triple between 2010 and 2030.2 
 
More than 17 million people in the world died from CVD in 2008 and a large 
proportion of the CVD deaths are preventable.1 Besides advancing age, gender, and 
genetic factors, most CVD risk factors are modifiable, such as tobacco use, physical 
inactivity, unhealthy diet, hypertension, diabetes, high blood lipid levels, and obesity. 
As major risk factors of CVD, obesity and overweight are major contributors to the 
disease burden worldwide4 and of great public health importance as major causes of 
morbidity and mortality.5 Obesity is accompanied by an activation of pro-inflammatory 
pathways5-7 and also linked to increased oxidative stress.8, 9 Inflammation is suggested 
to play a key role in the adverse effects of obesity, i.e. in type 2 diabetes (T2D) and 
CVD.5 Similarly, harmful oxidative stress plays a critical role in obesity-associated 
conditions such as diabetes, hypertension and atherosclerosis.8 
 
Given the increased CVD burden in the world, a better understanding of pathways 
leading to CVD is of great importance in order to identify new biomarkers, to better 
understand early CVD changes and to develop new pharmacological treatments. The 
view on adipose tissue has changed from a rather inactive tissue, with the main function 
of energy storage, to a bioactive organ expressing several secretory proteins, termed 
adipokines, providing a new link between adiposity and the development of CVD.10 An 
adipokine that has attracted much attention in recent years is adiponectin, which was 
first identified in 1996 as the most abundantly expressed transcript of adipose tissue.11 
Unlike most other proteins produced by adipose tissue, plasma concentrations of 
adiponectin decreases with increasing body mass index (BMI).12 Further, previous 
studies have linked adiponectin levels to a more beneficial cardiometabolic profile 
showing an inverse association with traits such as T2D,13 hypertension,14 
triglycerides,15 and myocardial infarction.16 
 
 
1.2 Adiponectin and the Adiponectin Receptors 
Adiponectin levels differ significantly between sexes, where women have higher levels 
than men.15 An inhibitory influence of androgens on adiponectin levels might offer a 
potential explanation for this difference.17, 18 The adiponectin levels are also higher in 
elderly, which can partly be explained by decreased renal function in aging and reduced 
adiponectin clearance.19 Several pharmaceutical agents are known to increase 
adiponectin such as lipid-lowering drugs20 and insulin-sensitizing thiazolidinediones 
(peroxisome proliferator activator receptor-γ agonists).21 Another example of 
the physiological importance of adiponectin for many biological systems is that it has 
been suggested to play a role in cancer.22 
 
Adiponectin is mainly expressed in adipose tissue, but expression has been detected in 
other tissues such as cardiomyocytes.23 The protein consists of 244 amino acids and has 
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several domains, including a N-terminal signal sequence, a variable domain, a collagen-
like domain, and a C1q-like globular domain at the C-terminus,11, 24 where the three-
dimensional structure of the globular domain of adiponectin shows structural 
similarities with tumor necrosis factor-α (TNF-α).25 Adiponectin is mainly found in its 
full-length form but also in small amounts as a globular domain fragment.26 
Adiponectin molecules assemble into several multimeric forms, which can be 
categorized as low-molecular weight (LMW), medium-molecular weight (MMW), and 
high-molecular weight (HMW) adiponectin.27 It has been indicated that the different 
forms might differ in biological effect,28, 29 although this remains to be fully 
established. 
 
Three adiponectin receptors have been identified - Adiponectin repector 1 (ADIPOR1), 
Adiponectin receptor 2 (ADIPOR2),30, 31 and T-cadherin.32 ADIPOR1 and ADIPOR2 
are seven-transmembrane domain proteins, structurally different from G-protein-
coupled receptors.30 Both these receptors are important for the regulation of glucose 
and lipid metabolism. They are predicted to have varying affinity for different forms of 
adiponectin and ADIPOR1 is associated with the activation of adenosine 
monophosphate kinase pathways, whereas ADIPOR2 activates peroxisome proliferator-
activated receptor-α pathways.30, 31 Further, APPL1 is suggested to be an adapter 
protein for ADIPOR1/2 signaling and to play a key role in the signal transduction of 
these receptors.33 T-cadherin is a suggested receptor for MMW and HMW adiponectin 
which was isolated after ADIPOR1/2.32 Genetic variation within the T-cadherin gene 
(CDH13) has been associated with circulating adiponectin levels.34-38 It is not clear how 
T-cadherin function since it does not contain an intracellular domain for signal 
transduction.32 
 
 
1.3 Adiponectin and the Heart 
The role of adiponectin in relation to cardiac geometry and function has attracted some 
attention in previous studies. Most of these studies were performed in small samples 
and in selected materials, e.g. patients with preexisting disease, such as T2D, 
hypertension or obesity, and have reported inverse associations between adiponectin 
and left ventricular (LV) mass,39-43 and diastolic dysfunction.41, 43 Similarly, one sample 
of healthy Japanese men found an inverse association between lower levels of 
adiponectin and LV hypertrophy assessed by electrocardiography (ECG).44 
 
In contrast to the beneficial cardiometabolic profile that has been reported for 
adiponectin in most studies, some studies have indicated that adiponectin increases in 
cardiac dysfunction. In a moderately large study of healthy individuals, circulating 
adiponectin increased in parallel with brain natriuretic peptide (BNP) and was 
positively associated with higher LV end-diastolic diameter which could indicate 
depressed cardiac function.45 The potential relationship between adiponectin and 
natriuretic peptides in the presence of cardiac dysfunction has also been indicated by 
studies showing increased levels of both adiponectin and N-terminal pro-brain 
natriuretic peptide (NT-proBNP) in patients with heart failure.46-48 
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1.4 Adiponectin and the Vasculature 
Several epidemiological studies have reported an association between adiponectin and 
vascular pathology.49-59 Previous studies have mainly focused on the intima-media 
thickness (IMT) and an inverse association has been reported in some49-52 but not all 
studies,53 possibly due to small study samples and concomitant diseases such as T2D49, 
51 or end-stage renal disease.51 The association between adiponectin and carotid plaques 
has been investigated in a few studies, but to our knowledge, none have found a 
significant association.50, 54 Also, the impact of adiponectin on morphological measures 
of echogenicity using the gray scale median (GSM) in the IM has not been studied 
before, and plaques remain to be studied in detail. Adiponectin have been negatively 
associated with arterial stiffness in some studies,55-57 but not all.52, 58, 59 Finally, studies 
on endothelial function and adiponectin have been inconclusive.60, 61 
 
 
1.5 Adiponectin, Oxidative Stress, and Inflammation 
Some previous epidemiological studies, most conducted in small samples and/or 
individuals with existing disease, have shown an association between adiponectin and 
pro- and anti-oxidative markers.8, 62-66 The association between adiponectin and 
glutathione remains to be fully elucidated, but an association between adiponectin and 
the ratio of oxidized and reduced glutathione has been suggested.62, 63 An inverse 
association between adiponectin and measures of lipid peroxidation has been reported 
in some studies,8, 64-66 but not all.67 
 
Previous studies have also indicated that the expression of adiponectin is down-
regulated by inflammatory cytokines such as TNF-α and potentially IL-6.68 Further, 
adiponectin exhibits anti-inflammatory effects on macrophages.69 However, in contrast 
with its anti-inflammatory effects, some studies have reported increased adiponectin 
levels in inflammatory and auto-immune conditions such as rheumatic diseases.70 
 
 
1.6 Genetic Determinants of Adiponectin Levels 
The adiponectin-encoding gene (ADIPOQ) have orthologous genes in several species, 
such as monkey, dog, rat, mouse, chicken, and the domain structures are highly 
conserved among species indicating its importance for biological functions.24, 71 The 
heritability estimates for adiponectin are moderate to high, with 30-70% of the 
phenotypic variability explained by genetic variation.72-74 
 
Early candidate gene studies that mainly focused on variation within ADIPOQ yielded 
inconclusive results.75-80 A study applying deep re-sequencing of ADIPOQ indicated 
that seven single nucleotide polymorphisms (SNPs) within the region had an 
independent effect on adiponectin levels.81 The discrepancies could be explained by 
limited sample sizes, as well as heterogeneity of the SNPs studied, and ethnic 
differences. 
 
One way to identify novel genetic loci and to overcome some of the limitations in 
candidate gene studies is to perform genome-wide association (GWA) studies in 
sufficiently large study samples. GWA studies of European individuals have identified 
genome-wide significant signals at ADIPOQ.34, 82, 83 Further, a robust signal has been 
identified at the ADP-ribosylation factor-like 15 gene (ARL15), where the variant 
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associated with adiponectin also was associated with a higher risk of CHD and 
moderately associated with T2D.83 Studies in Asian populations have identified a 
strong GWA-significant signal at CDH13,36-38 and a moderate to strong signal has later 
been found in Europeans.34, 35 An uncommon haplotype at KNG1-ADIPOQ was 
identified in a study of Asians38 and a follow-up study identified a rare coding variant 
within ADIPOQ, explaining up to 17.1% of the phenotypic variability.84 However, 
depending on which allele an individual carried at this non-synonymous variant, the 
amino acid change affected the binding-affinity of the antibodies in the adiponectin 
immunoassay, which resulted in artificially different levels of adiponectin between 
carriers of the different alleles.84 A recent large meta-analysis of European individuals, 
with additional samples from other ethnicities, confirmed two known loci (ADIPOQ, 
CDH13) and identified eight novel loci. A multi-SNP risk score, calculated as the 
additive effect of the adiponectin-decreasing alleles was associated with higher T2D, 
triglycerides, waist-hip ratio, fasting insulin and 2-h glucose from an oral glucose 
tolerance test, but somewhat unexpectedly lower BMI.34 
 
Although several genetic regions have been identified to be associated with adiponectin 
levels, a large fraction of the expected phenotypic variability due to genetic variation 
remains to be explained. Previous studies have mainly focused on common variants 
with a minor allele frequency above 5% and uncommon or rare variants with a lower 
frequency remain largely unexplored on a genome-wide level. 
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2 AIMS 
The overall aim of this thesis was to assess the genetic determinants of adiponectin, and 
to investigate the relation between adiponectin and markers of early CVD. The specific 
aims for each study were: 
 
I. To elucidate the association between adiponectin and cardiac geometry and 
function in two cross-sectional samples of elderly, and to further assess the role 
of natriuretic peptides. 
II. To evaluate associations between circulating adiponectin and comprehensive 
measures of vascular function and morphology in a large sample of individuals 
from the community. 
III. To investigate the importance of a broad set of well-recognized oxidative stress 
and inflammatory markers, representing different pathways, in relation to 
adiponectin in a large community-based sample of elderly. 
IV. To examine the impact of the mutational burden of rare genetic variants on 
adiponectin levels. 
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3 STUDY SAMPLES 
Data from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) 
was used in all studies, whereas the Uppsala Longitudinal Study of Adult Men 
(ULSAM) study was used in Study I and IV. The clinical characteristics of all 
individuals with adiponectin measurements in PIVUS and ULSAM are presented in 
Table 1. Further, the IMPROVE study was used in the replication stage of Study IV. 
 
 
Table 1. Clinical characteristics of all individuals with available adiponectin 
measurements in PIVUS and ULSAM. 
 
  
PIVUS 
(n=1,007) 
ULSAM 
(n=1,205) 
Age 70.1 (0.2) 71.0 (0.6) 
Women (%) 50 0 
BMI (kg/m2) 27.0 (4.3) 26.3 (3.4) 
Fasting plasma glucose (mmol/L) 6.0 (1.8) 5.8 (1.4) 
Anti-diabetic treatment (%) 6 6 
Total cholesterol (mmol/L) 5.4 (1.0) 5.8 (1.0) 
HDL cholesterol (mmol/L) 1.5 (0.4) 1.3 (0.3) 
Lipid lowering treatment (%) 16 9 
Systolic blood pressure (mmHg) 150 (22) 147 (19) 
Antihypertensive treatment (%) 31 35 
Creatinine (µmol/L) 80 (19) 94 (15) 
Smoking (%) Never: 48 
Previous: 41 
Current: 11 
Never: 38 
Previous: 42 
Current: 20 
Adiponectin (mg/L) 7.1 (4.3) 10.4 (4.3) 
 
 
3.1 The Prospective Investigation of the Vasculature in Uppsala Seniors 
The PIVUS study has been described in detail previously85 and online 
at http://www.medsci.uu.se/pivus/pivus.htm. Individuals at the age of 70 years, living 
in the community of Uppsala, Sweden, between April 2001 and June 2004 were 
randomly selected from the community register and invited to participate. Invitations 
were sent out in a randomized order by letter within 2 months of their 70th birthday in 
order to standardize for age. Out of 2,025 subjects invited, 1,016 subjects participated 
(50.1%) with an equal proportion men and women. All participants were asked to 
answer a questionnaire with detailed questions about their medical history, smoking 
habits and regular medication. 
 
The physical examination was performed in the morning after an overnight fast with no 
medication or smoking allowed after midnight. During the examination, participants 
were in supine position in a quiet room at constant temperature for a total of four hours. 
At least 30 minutes passed between the different tests performed. Lipid variables and 
blood glucose were measured with standard laboratory techniques. Blood pressure was 
measured with a calibrated mercury sphygmomanometer in the non-cannulated arm and 
the mean of three recordings was used. 
 
In order to characterize cardiovascular disorders and medications of non-participants, 
data on such factors was collected for 100 individuals that did not participate in PIVUS. 
Compared with the participants, these individuals had on average a similar frequency of 
myocardial infarction, coronary revascularization, anti-hypertensive treatment, statin 
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use, and insulin treatment, but higher a frequency of diabetes, congestive heart failure 
and stroke. 
The PIVUS study was approved by the Ethics committee of Uppsala University, and all 
participants provided written informed consent. 
 
3.2 The Uppsala Longitudinal Study of Adult Men 
The ULSAM study has been described elsewhere86 and on the Internet 
at http://www.pubcare.uu.se/ULSAM/. The study is of cohort design and was initiated 
in 1970-73 when all 50-year-old men living in Uppsala County, Sweden were invited to 
participate. These individuals, born between 1920 and 1924, were selected from the 
register of the County Council. At the first examination at age 50, 2,841 men were 
invited out of which 2,322 participated (81.7%). The participants were then re-
examined at the approximate age of 71 years, where all participants in the first 
examination at age 50 were traced by their ten-digit social security number and invited 
to participate. The re-examination was carried out between August 1991 and May 1995 
in which 1221 out of 1681 invited subjects participated (73%), excluding 422 subjects 
that had died and 219 that had moved out of the Uppsala region (Figure 1). 
 
Figure 1. Study design of the Uppsala Longitudinal Study of Adult Men. 
 
 
 
The participants were asked to answer a questionnaire on general and medical 
background. Further, smoking habits were assessed during an interview. The 
examination was performed in a fasting state, where lipid variables and blood glucose 
were measured with standard laboratory techniques. After at least 10 minutes of rest, 
blood pressure was measured with a calibrated mercury sphygmomanometer and the 
mean of two recordings was used. 
The ULSAM study was approved by the Ethics committee of Uppsala University, and 
all participants provided written informed consent. 
 
422 died, 219 moved 
2,841 invited 
2,322 participated 
Examination at age 50 (1970-73) 
1,221 participated 
1,681 invited 
Examination at age 71 (1991-95) 
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3.3 The IMPROVE study 
The IMPROVE study has been described before.87 It is a longitudinal study designed to 
investigate if the carotid artery intima-media thickness (IMT), as well as overall IMT 
progression can predict new vascular events in high-risk individuals of CVD. This 
observational study recruited participants at seven centres in Finland, France, Italy, the 
Netherlands, and Sweden; including 3,711 individuals (men and women) aged from 54 
to 79 years and free from CVD at baseline, but with at least three vascular risk factors. 
The study was approved by the Ethics committee of Karolinska Institutet and the 
participants provided informed consent for general participation and for genotyping. 
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4 STUDY DESIGNS AND METHODS 
4.1 General Methods 
4.1.1 Transformation of Adiponectin 
In Study I-III, we standardized adiponectin values through Z-score transformation, 
separately in men and women and then pooled the transformed values. The distribution 
of the transformed variable using this method is centered on a mean of 0 with a 
standard deviation of 1. This mean and standard deviation is the same for men and 
women, which will adjust for the potentially confounding effect of sex when 
performing a regression analysis with the transformed variable. 
 
In Study 4, adiponectin is the outcome in the regression models and since phenotypic 
outliers can have a larger impact on the results when focusing on rare genetic variation, 
we applied an inverse normal transformation of adiponectin according to Blom. As for 
the Z-score transformation, this was done separately for men and women and the 
pooled. 
 
 
4.1.2 Significance Level and Multiple Testing 
In Study I-III, a P-value < 0.05 was considered to be statistically significant. Given the 
prior knowledge from previous studies indicating that adiponectin was associated with 
cardiovascular pathways, this alpha-level was in general considered strict enough when 
discussing the results. However, in order to assess the impact of multiple testing on the 
22 tests performed in Study III, we performed a Holm-Bonferroni correction88 to 
highlight the number of tests for the reader. 
 
Regarding Study IV, previous studies had shown that much of the adiponectin 
phenotypic variance is explained by genetic factors and that a large fraction of the 
source of this heritability remains to be discovered. However, which genetic regions to 
focus on are not known, so we tested all transcript regions available in the UCSC 
transcript database. This untargeted approach calls for strict adjustment for multiple 
testing and a P-value < 1.7×10-6 was considered significant in this study (Bonferroni-
correction for 30,000 tests). The Bonferroni-correction approach aims to eliminate false 
positives with an overall family-wise error rate of 0.05. Another approach to adjust for 
multiple testing is the false discovery rate which is more liberal in the sense that it 
controls for the proportion of accepted false positives in relation to the total number of 
accepted signals. However, given the risk of including false positives and that we had 
limited resources to assess this in an independent replication sample; the Bonferroni-
approach was selected for the present study. 
 
 
4.1.3 Adiponectin Measurements 
Adiponectin in samples from PIVUS, frozen for 1-3 years, was analysed with a double-
antibody radioimmunoassay (RIA; Millipore, Billerica, MA, USA, previously Linco 
research). At low levels (2–4 µg/ml), the within-assay coefficient of variation (CV) was 
6% and the between-assay CV was 14%, whereas at high levels (26–54 µg/ml) the 
within-assay CV was 3% and the between-assay CV was 8%. 
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In ULSAM, adiponectin was measured in samples frozen in -70ºC for 11±2 years, 
without previous thaw-freeze cycles. A validated in-house time-resolved 
immunofluorometric assay based on commercial reagents from R&D Systems 
(Abingdon, UK) was used. The within-assay and between-assay CV averaged less than 
5 and 10%, respectively. 
 
The same method described for PIVUS was used to measure adiponectin in the 
replication sample IMPROVE (Study IV). 
 
 
4.1.4 Measurement and Definition of Additional Covariates 
NT-proBNP was measured in PIVUS and ULSAM with a sandwich immunoassay on 
an Elecsys 2010 (Roche Diagnostics, Basle, Switzerland) at an analytical range of 20 to 
35,000 ng/l. The total coefficient of variation was 3.3% at a level of 209 ng/l and 3.0% 
at a level of 7.4 ng/l. 
 
BMI was calculated as the ratio between weight (kg) and height squared (m2). The 
homeostasis model assessment insulin resistance index (HOMA-IR) was defined as 
(fasting plasma glucose × serum insulin)/22.5.89 Diabetes was defined as diabetes 
medication or elevated fasting glucose (in blood ≥ 6.1 mmol/L or in plasma ≥ 7 
mmol/L).90 Estimated glomular filtration rate from cystatin C (eGFR), representing 
kidney function, was calculated according to a previous publication91 as eGFR 
(mL/min/1.73m2) = 79.901×(cystatin C in mg/L)-1.4389. 
 
 
4.2 Study I 
4.2.1 Exclusions 
In PIVUS, 954 participants were included after the exclusion of participants without 
valid adiponectin measurements (n=9), echocardiography readings (n=30), or all 
clinical characteristics needed for multivariable analysis (n=23). An echocardiographic 
examination was performed in a random sub-sample of 482 individuals in ULSAM. 
After further exclusion of individuals without valid adiponectin measurements (n=16) 
or all clinical measures used in the analyses (n=39), the eligible sample was 427 
individuals. 
 
 
4.2.2 Echocardiographic Examination 
The echocardiographic examination was performed approximately one week after the 
main examination using comprehensive two-dimensional and Doppler 
echocardiography, with an Acuson XP124 cardiac ultrasound unit (Acuson, California, 
USA), in both study samples.92 The echocardiographic measures included LV end-
diastole diameter (LVEDD), left atrial diameter, ejection fraction, LV isovolumic 
relaxation time, E/A ratio, interventricular septal thickness (IVS), LV posterior wall 
thickness (PW). LV relative wall thickness (RWT) was calculated as 
(IVS+PW)/LVEDD and LV mass (LVM) as 0.8×(1.04×([IVS+LVEDD+PW]3-
LVEDD3)+0.6 g.93 LV mass index (LVMI) was obtained by indexing LVM divided by 
height to the power of 2.7 (LVM/m2.7).94 Ejection fraction was calculated from M-
mode recordings according to the method of Teichholz.95 LV geometry was categorized 
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as: normal (LVMI ≤51 g/m2.7; RWT ≤0.45), eccentric LV hypertrophy (LVMI >51 
g/m2.7; RWT ≤0.45), concentric remodeling (LVMI ≤51 g/m2.7; RWT >0.45), or 
concentric LV hypertrophy (LVMI >51 g/m2.7; RWT >0.45).96 
 
 
4.2.3 Statistical Main Analysis 
In order to promote normality, E/A-ratio and fasting glucose values were 
logarithmically transformed. The relation of adiponectin with echocardiographic 
measures (LVMI, RWT, LVEDD, left atrial diameter, ejection fraction, isovolumic 
relaxation time, E/A-ratio) as dependent variables was tested in separate linear 
regression models. Age- and sex-adjusted regression models were performed, as well as 
multivariable linear regression models adjusted for age, sex, BMI, systolic blood 
pressure, antihypertensive treatment, anti-diabetic treatment, lipid lowering medication, 
log fasting blood glucose, total cholesterol, HDL cholesterol, creatinine, and smoking 
(no, former, current). All analyses were performed in Stata 10.1 (Stata Corporation, 
College Station, TX). 
 
 
4.2.4 Additional Analyses 
In order to investigate the potentially mediating role of natriuretic peptides in the 
relation of adiponectin with cardiac function, NT-proBNP was added to the 
multivariable-adjusted models with ejection fraction, isovolumic relaxation time or 
E/A-ratio as outcomes. We further assessed if sex was an effect-modifier of the studied 
associations, by adding two-way interaction terms between sex and adiponectin to each 
model with the cardiovascular variables as outcomes. Also, to avoid a potentially 
confounding effect of co-morbidities with heart disease, the analyses were also 
performed in sub-samples consisting of 804 (PIVUS) and 356 (ULSAM) individuals 
without history of myocardial infarction, heart failure, angina pectoris or interventional 
treatment of the coronary arteries, or with significant valvular diseases detected on the 
echocardiogram. Adiponectin levels in relation to groups of cardiac geometry were 
calculated as age- and sex-adjusted least square means of adiponectin grouped by 
categories of cardiac geometry in the PIVUS study. 
 
 
4.3 Study II 
4.3.1 Exclusions 
After the exclusion of individuals without valid measures of adiponectin (n=9) or 
missing data on any of the clinical covariates needed for multivariable analysis (n=25), 
the eligible study sample consisted of 981 participants. 
 
 
4.3.2 Measurements of Vascular Function and Morphology 
The examination of the carotid artery was done by external B-mode ultrasonography 
(Acuson XP128 with a 10MHz linear transducer, Acuson Mountain View, California, 
USA) as has been described before.97 Frozen ultrasound images were saved by the 
ultrasonographer and further digitized and imported into the Artery Measurement 
Software (AMS)98 for analysis of IMT and GSM. The occurrence of plaques was 
recorded on both sides for the common carotid artery (CCA), the bulb and the internal 
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carotid artery. IMT was evaluated in the far wall in the CCA, 1–2 cm proximal to the 
bulb, excluding overt plaques from the measurement. The borders of the IMT were 
identified by the AMS software and IMT was calculated from about 100 discrete points 
through a 10 mm long segment. The IMT value presented was the mean value from 
both sides. Intima-media segments to be evaluated for IM-GSM were defined by a 
manually placed region of interest (ROI) and IM-GSM was analyzed from individual 
pixels within the ROI on a scale from 0 (black) to 256 (white). The GSM was 
calculated as the mean from both sides, with the adventitia as a reference for white and 
the blood as a reference for black. The GSM of plaques was analyzed by placing the 
ROI within a plaque if such existed, and by the use of the same software as IM-GSM. If 
plaques were present in both carotids, the GSM in the most echolucent plaque was 
selected, since previous studies have demonstrated echolucent plaques to be the most 
pathological form.99, 100 
 
Pulse wave analysis was performed with a micromanometer-tipped probe 
(Sphygmocor, Pulse Wave Medical Ltd, Sydney, Australia) using the mean value of 10 
recordings. The central pulse pressure was calculated as the difference between central 
systolic blood pressure and central diastolic blood pressure. CCA distensibility was 
calculated as the percentage change in the maximum to minimum diameter divided by 
the central pulse pressure obtained by pulse-wave analysis.101 
 
Flow-mediated dilation (FMD) was assessed with B-mode ultrasound imaging 2-3 cm 
over the elbow, after placing a cuff below the elbow, inflated to a pressure of at least 50 
mmHg over resting systolic blood pressure for 5 min. FMD was calculated as the 
maximal brachial artery diameter after cuff release minus diameter at rest, divided by 
diameter at rest. We placed an arterial cannula in the brachial artery, and forearm blood 
flow (FBF) was calculated from at least five measurements by venous occlusion 
plethysmography (Elektromedicin, Kullavik, Sweden) with the strain-gauge technique. 
Endothelial-dependent vasodilation (EDV) was defined as FBF during infusion of 50 
µg/min of acetylcholine minus resting FBF, divided by resting FBF. Endothelial-
independent vasodilation (EIDV) was defined as FBF during infusion of 10 µg/min of 
sodium nitroprusside minus resting FBP, divided by resting FBF.85 The CV of the 
ultrasound assessments when repeating the measurements were 3% for baseline 
brachial artery diameter, 29% for FMD, 8% for EDV, and 10% for EIDV.85 
 
 
4.3.3 Statistical Main Analysis 
CCA distensibility, EDV, EIDV and fasting glucose were logarithmically transformed 
in order to achieve normality. In separate linear regression models, the association 
between adiponectin and measures of vascular morphology (IMT, plaque presence, 
plaque GSM and IM-GSM) as well as vascular function (log CCA distensibility, FMD, 
log EDV and log EIDV) was assessed. Adjustments were made for potential 
confounders including age, sex, BMI, systolic blood pressure, antihypertensive 
treatment, antidiabetic treatment, lipid lowering medication, log fasting blood glucose, 
total cholesterol, HDL cholesterol, creatinine, and smoking (no, former, current). Stata 
version 10.1 (Stata Corporation, College Station, TX) was used for all analyses. 
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4.3.4 Additional Analyses 
A two-way interaction term of adiponectin and sex was incorporated with each vascular 
measure as dependent variables in separate models in order to test the effect 
modification by sex. In order to assess the potentially confounding effect of co-
morbidities with pre-existing clinical CVD, analyses were also performed in sub-
samples consisting of 822 individuals without history of myocardial infarction, heart 
failure, angina pectoris or interventional treatment of the coronary arteries, or with 
significant valvular diseases detected on the echocardiogram. 
 
 
4.4 Study III 
4.4.1 Exclusions 
To exclude individuals with acute infections, chronic inflammatory disorders or blood 
malignancies, participants with CRP > 10 mg/L or leukocyte count > 10 × 109 cells/L 
(n=65) were excluded from the present study. Further exclusions were made of 
participants without valid measures of adiponectin (n=1) or of those missing any 
covariate used in the regression analyses (n=21). Thus, 929 participants were eligible 
for the study. 
 
 
4.4.2 Measurements of Oxidative Stress and Inflammatory Markers 
Baseline conjugated dienes of LDL (BCD-LDL) were measured using a previously 
validated method,102 with a CV for within-assay and between-assay of 4.4 and 4.5%, 
respectively. After precipitation of serum LDL with buffered heparin, BCD-LDL was 
measured spectrophotometrically. Levels of serum oxidized LDL were determined with 
enzyme-linked immunoabsorbent assay (ELISA) kits (Mercodia, AB); within-assay CV 
was 6.3% and between-assay CV was 4.7%. Autoantibodies to OxLDL were measured 
with an ELISA kit (BioMedica), with intra-assay and inter-assay CVs of 4.3 and 6.0%, 
respectively. All forms of glutathione, conjugated dienes (CD) and total anti-oxidative 
capacity (TAOC) values were measured and calculated as described previously.103 In 
brief, TGSH and GSSG were measured through enzymatic reactions, and GSH was 
further calculated as the difference between TGSH and GSSG. Conjugated dienes, 
formed after double-bound rearrangements in polyunsaturated fatty acid residues in a 
free radical reaction, were measured spectrophotometrically. TAOC was measured by 
assessing the ability of serum samples to inhibit linolenic acid peroxidation. 
Homocysteine was measured by using Axis® Homocysteine Enzyme Immunoassay 
(Axis-Shield Diagnostics Ltd.) with an intra-assay coefficient of 6.8%. 
 
High sensitive C-reactive protein (CRP) and intercellular adhesion molecule-1 (ICAM-
1) was measured with commercially available ELISAs (Medix Biochemica, 
Kauniainen, Finland and R&D System Europe Ltd, Abingdon, Oxon, UK, 
respectively). The leukocyte count was measured by standard laboratory techniques at 
Uppsala University Hospital. Remaining inflammatory markers were analyzed with the 
Evidence® array biochip analyzer (Randox Laboratories Ltd, Crumlin, UK).104 The 
functional sensitivity for the inflammatory markers was as follows: IL-6: 0.3 pg/mL; 
IL-8: 1.5 pg/mL; TNF-α 1.8 pg/mL; MCP-1 19.4 pg/mL; VCAM-1: 31 ng/mL; E-
selectin: 3.1 ng/mL; P-selectin: 11.2 ng/mL; L-selectin 32.8 ng/mL; leukocyte count 
0.2 × 109 cells/L. IL-1α, IL-1β, IL-2, IL-4, IL-10, and interferon-γ were included in the 
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Evidence® array biochip cytokine panel, but were not evaluated further due to 
insufficient sensitivity for measurements in the present sample. 
 
 
4.4.3 Statistical Main Analysis 
In order to achieve a normal distribution of the residuals of the regression models, all 
oxidative and inflammatory markers except GSH, conjugated dienes, TAOC, BCD-
LDL, OxLDL, MCP-1, P-selectin, L-selectin, and leukocyte count were transformed, as 
well as the covariates HOMA-IR and triglycerides. Natural log was used for all 
transformations, except TNF-α for which a reciprocal root transformation was 
performed. 
 
The association between adiponectin and outcomes including oxidative stress 
(conjugated dienes, homocysteine, TAOC, OxLDL, OxLDL antibodies, BCD-LDL, 
GSH, TGSH, glutathione disulfide), circulation interleukins (IL-6, IL-8), other 
cytokines (TNF-α, MCP-1, EGF, VEGF), cell adhesion molecules (VCAM-1, ICAM-1, 
E-selectin, P-selectin, L-selectin) and systemic inflammatory markers (CRP, leukocyte 
count) was assessed in age- and sex-adjusted, as well as multivariable-adjusted models. 
The multivariable-adjusted models were adjusted for age, BMI, antihypertensive 
treatment, log HOMA-IR, anti-diabetic treatment, total cholesterol, high-density 
lipoprotein (HDL), log triglycerides, lipid-lowering medication, eGFR, and smoking 
(no, former, current). 
 
The statistical software package Stata 11.2 (Stata Corporation, College Station, TX, 
USA) was used for all analyses. 
 
 
4.4.4 Additional Analyses 
To address the potential effect modification by sex, previous CVD or BMI, we added 
two-way interaction terms to the multivariable-adjusted models, in separate models for 
adiponectin × sex, adiponectin × previous CVD, and adiponectin × BMI. We also re-
ran the multivariable-adjusted model stratified by sex, previous CVD and overweight 
(BMI < 25 and BMI ≥ 25) in separate models. In an exploratory analysis, we also tested 
if the ratio of reduced and oxidized glutathione, calculated as GSH/GSSG, was 
associated with adiponectin in age- and sex-adjusted, as well as multivariable-adjusted 
models. The multivariable regression model was further performed after excluding all 
individuals with signs of chronic kidney disease (eGFR < 50 mL/min/1.73m2) for all 
significant associations in the main multivariable-adjusted model. 
 
 
4.5 Study IV 
4.5.1 Exclusions 
In PIVUS, the analyses were performed in 839 individuals after exclusions based on 
missing microarray genotyping data (n=34), failing sample quality control (QC) 
(n=33), missing adiponectin measurements (n=1), and individuals with diabetes 
(n=109). Using the same exclusion criteria for ULSAM, 984 individuals were included, 
after the exclusion of participants with missing microarray genotyping data (n=5), 
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failing sample QC (n=37), missing adiponectin measurements or covariates (n=74), and 
individuals with diabetes (n=121). 
 
 
4.5.2 Preparation of Genotype Data and Imputation 
Genotyping was performed using the Illumina OmniExpress and Illumina 
Metabochip in PIVUS, and Illumina Omni2.5M and Illumina Metabochip in 
ULSAM. For both PIVUS and ULSAM, sample QC was first performed for the 
Omni-chip. For individuals that passed this QC, the QC for Metabochip was then 
performed. The SNP QC was performed for each data source separately, and the 
quality-controlled data of OmniExpress or Omni2.5 and Metabochip was then 
merged. Samples were excluded from both studies based on: 1) genotype call rate 
<95%; 2) heterozygosity >3 standard deviations; 3) gender discordance; 4) duplicated 
samples; 5) identity-by-descent match; and 6) ethnic outliers. General SNP exclusion 
criteria of genotyped data before imputation included: 1) monomorphic SNPs; 2) 
Hardy-Weinberg equilibrium P-value<1×10-6; 3) genotype call rate<0.99 (SNPs with 
MAF<5%) or <0.95 (SNPs with MAF≥5%); and 4) MAF<1%. In ULSAM, for 
Omni2.5, further SNP exclusions were made if a SNP had large position 
disagreements, did not map in the genome, mapped more than once in the genome or 
had bad probe assays. 
 
In PIVUS, 958 out of 982 samples passed QC for the OmniExpress, and out of those, 
949 passed QC on the Metabochip. Further, 645,318 out of 733,202 OmniExpress 
SNPs, and 123,771 out of 185,801 Metabochip SNPs passed QC; hence, the 
genotyped data in PIVUS consisted of 949 samples and 738,879 SNPs.  
 
In ULSAM, 1,179 out of 1,216 samples passed QC for the Omni2.5, which further 
passed QC and were available on the Metabochip. Further, 1,531,196 out of 
2,379,855 Omni2.5 SNPs and 119,775 out of 185,801 Metabochip SNPs passed QC; 
hence, the genotyped data in ULSAM consisted of 1,179 samples and 1,621,833 
SNPs.  
 
Imputation was performed after the QC of the genotype data for each cohort in 
IMPUTE v.2.2.2 using haplotypes from the 1000 Genomes, March 2012 release 
(multi-ethnic panel on NCBI build 37 [b37]). Population substructures were captured 
by principal components (PCs), calculated in PLINK 1.07 using the multidimensional 
scaling approach.105 
 
 
4.5.3 Statistical Main Analysis 
We investigated if the proportion of rare variants within a gene, where the individual 
carried the minor allele, was associated with adiponectin levels, using the statistical 
method implemented in GRANVIL 2.0.1.106 A burden test like this is used to increase 
power to detect associations of rare or uncommon variants with the outcome. The 
regression analysis was performed with inverse normal transformed adiponectin as the 
dependent variable and adjusting for PC1, PC2, as well as BMI in non-diabetic 
individuals. Rare variants were defined to have a MAF<1% or MAF<5% and SNPs 
with an information quality metric below 0.4 (indicating suboptimal imputation) were 
excluded from the analysis. Gene boundaries were defined based on the UCSC Human 
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Genome database transcript regions’ start and stop position on NCBI build 37 and 
extracted using the UCSC Table Browser (http://genome.ucsc.edu/cgi-bin/hgTables). 
The association tests were performed using: 1) all available markers; 2) coding markers 
only; and 3) non-synonymous markers only, where the marker lists were built from the 
publically available 1000 Genomes annotation file. The association results from 
GRANVIL for PIVUS and ULSAM were combined in a sample size-weighted Z-score 
meta-analysis assuming fixed effects in the software METAL,107 separately for each 
subset of markers and for the two MAF cutoffs. 
 
 
4.5.4 Additional Analyses 
In order to identify independent SNPs around the ADIPOQ gene that are associated 
with adiponectin, an association test was performed using SNPTEST 2.4.1,108 in a 
forward selection conditional analysis, where independent signals where considered 
down to a P-value of 1×10-5. We then tested if the rare variant burden test of the 
ADIPOQ gene obtained from GRANVIL was independent of these SNPs by 
conditioning the rare variant burden test on the genotype dosages of the independent 
ADIPOQ SNPs. 
 
In order to assess the predicted impact on protein level of the coding marker selected 
for replication, we performed an analysis in two bioinformatics tools used to annotate 
coding non-synonymous SNPs, Polyphen-2109 and PANTHER.110 
 
 
4.5.5 Replication in the IMPROVE Study 
The genotyping of the variant selected for replication (chr12:1702929) in IMPROVE 
was performed using a custom SNP genotyping array from Applied Biosystems and 
called using Applied Biosystems’ SDS 2.3 software (call rate 97.4%). In total, 3,340 
individuals had valid measures for adiponectin and available genotype data, and after 
further exclusions of individuals with diabetes, 2,412 were included in the analysis for 
which the regression model described for PIVUS and ULSAM was performed. 
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5 RESULTS 
5.1 Adiponectin and Measures of Cardiac Geometry and Function 
In multivariable-adjusted models including BMI, circulating adiponectin was inversely 
associated with ejection fraction in PIVUS, as well as in ULSAM (Table 2). For each 
standard deviation increase of adiponectin, ejection fraction decreased with 1.2% 
(PIVUS) or 1.3% (ULSAM) after taking potential confounders into account. 
 
Table 2. Association between adiponectin and ejection fraction in PIVUS and 
ULSAM. 
 
Associations between adiponectin and ejection fraction (%) 
 
Age- and sex-adjusted 
 
Multivariable-adjusted 
  β (95% CI) P-value   β (95% CI) P-value 
PIVUS; n=810 -0.73 (-1.25; -0.20) 0.007   -1.16 (-1.73; -0.58) < 0.0001 
ULSAM; n=385 -0.91 (-1.86; 0.04) 0.059   -1.35 (-2.41; -0.29) 0.013 
 
In PIVUS, adiponectin was inversely associated with LVMI, RWT, and left atrial 
diameter in age- and sex-adjusted analyses. Consistent with this, adiponectin 
concentrations were significantly lower in individuals with eccentric hypertrophy, 
concentric remodeling, and concentric hypertrophy compared with individuals with 
normal cardiac geometry (Figure 2). The associations of adiponectin with LV 
geometry were non-evident in multivariable-adjusted analyses. In secondary analyses, 
associations between adiponectin and LV mass (without indexing for height) were 
almost identical to those incorporating LVMI. Exploratory analyses demonstrated that 
BMI was the most important confounder of the associations of adiponectin and cardiac 
geometry, as the addition of BMI to the age- and sex-adjusted analyses rendered all 
associations non-significant (P=0.52; 0.14; and 0.91). In ULSAM, adiponectin was not 
significantly associated with measures of cardiac geometry in any model. 
 
Figure 2. Age- and sex-adjusted least square means of adiponectin grouped by 
categories of cardiac geometry in the PIVUS study (N=954). 
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Sex was found to be an effect modifier only in the association of adiponectin with 
ejection fraction (P-value for interaction=0.063); the association was evident in men (β, 
-1.62; 95% confidence interval [CI], -2.50, -0.75; P-value<0.0001), but not in women 
(β, -0.27; 95% CI, -1.02, 0.47; P-value=0.47). The inverse relation between adiponectin 
and ejection fraction remained similar when excluding individuals with known prior 
CVD (β, -0.69; 95% CI, -1.28, -0.11; P-value=0.019; β, -1.62; 95% CI, -2.70, -0.55; P-
value=0.003, in PIVUS and ULSAM, respectively). Exploratory analyses revealed that 
HDL cholesterol and BMI increased the magnitude of the association between 
adiponectin and ejection fraction when added to the age- and sex-adjusted model. LV 
mass had no effect on the association between adiponectin and ejection fraction when 
added to the multivariable model, nor did further adjustment for CRP or HOMA-IR 
(data not shown). 
 
To address the role of natriuretic peptides in mediating the association of adiponectin 
with cardiac function, we added NT-proBNP to the multivariable-adjusted model with 
ejection fraction as outcome. The association between adiponectin and ejection fraction 
was attenuated in both PIVUS (β, -0.68; 95% CI, -1.25, -0.10; P=0.021) and ULSAM 
(β, -0.75; 95% CI, -1.84, 0.35; P=0.18). Consistent with the above sex-stratified 
analyses, the association between adiponectin and ejection fraction was attenuated, but 
still significant in men and non-significant in women. Further, the attenuation was less 
pronounced in individuals without prior CVD (β, -0.69 and -0.61; 95% CI, -1.28, -0.11 
and –1.20, -0.03, without and with adjustment for NT-proBNP, respectively) compared 
with a sub-sample with individuals having prior CVD (β, -2.30 and -1.00; 95% CI, -
3.90, -0.69 and –2.76, -0.75, without and with adjustment for NT-proBNP, 
respectively). 
 
With our sample sizes, we had at least 85% (PIVUS) or 81% (ULSAM) statistical 
power to detect an increment to the model R2 of 0.01 (PIVUS) or 0.02 (ULSAM) for all 
measures of cardiac function and geometry (at α=0.05). 
 
 
5.2 Adiponectin and Measures of Vascular Function and Morphology 
The main results are presented in Table 3. There was a positive association between 
adiponectin and increased vascular function, measured as CCA distensibility, 
independent of potential confounders. CCA distensibility increased with 0.04 %/mmHg 
for each standard deviation increase of adiponectin in both the age- and sex-adjusted 
model, as well as in the multivariable-adjusted model. Further, adiponectin was 
positively associated with measures of vascular morphology (IM-GSM and plaque 
GSM) independent of the confounders included in the regression models. For each 
standard deviation increase of adiponectin, there was an increase of 2.1 and 3.1 units of 
IM-GSM and plaque GSM, respectively, in the multivariable-adjusted model. 
 
Table 3. Association between adiponectin and measures of vascular function and 
morphology that remained significant after adjustment for potential confounders. 
 
 
Associations with adiponectin 
 
Age- and sex-adjusted 
 
Multivariable-adjusted 
  β (95% CI) P-value   β (95% CI) P-value 
log CCA distensibility (%/mmHg); n=856 0.04 (0.00; 0.07) 0.025 
 
0.04 (0.00; 0.07) 0.034 
IM-GSM; n=957 4.73 (3.30; 6.16) < 0.0001 
 
2.06 (0.54; 3.58) 0.008 
Plaque GSM; n=575 5.91 (3.42; 8.40) < 0.0001   3.11 (0.36; 5.86) 0.027 
   19 
 
Adiponectin was also positively associated with log EDV and log EIDV in age- and 
sex-adjusted analyses, but the association did not remain significant in the 
multivariable-adjusted model. Exploratory analysis demonstrated BMI and HDL 
cholesterol to confound the association with both EDV and EIDV. No association was 
found between adiponectin and the other outcomes tested. 
 
The associations of adiponectin with IM-GSM, plaque GSM and CCA distensibility 
were of similar effect size in men and women (data not shown). The effect size of the 
relation of adiponectin with IM-GSM and CCA distensibility were similar when 
excluding individuals with prior CVD compared with the total population (β, 2.06; 95% 
CI, 0.34, 3.78; P=0.019 and β, 0.05; 95% CI, 0.01, 0.09; P=0.007, respectively). The 
association between adiponectin and plaque GSM was highly significant in individuals 
with prior CVD (β, 6.43; 95% CI, 1.61, 11.26), but did not remain significant in a 
healthy subsample (β, 1.47; 95% CI, -1.93, 4.86). Substituting BMI with waist 
circumference or waist-hip ratio in the multivariable-adjusted models had no substantial 
effect on the associations of adiponectin with the vascular measures. Also, further 
adjustment for HOMA-IR or the presence of any type of medication had no effect on 
the results. 
 
In the total sample we had at least 86% statistical power to detect an increment to the 
model R2 of 0.010 for all vascular measures (at α=0.05), except plaque GSM for which 
we had 88% power to detect an increment of the model R2 of 0.015. 
 
 
5.3 Oxidative Stress and Inflammatory Markers in relation to 
Adiponectin 
In age- and sex-adjusted, as well as multivariable-adjusted models, adiponectin was 
positively associated with GSH and log TGSH, whereas a negative association with 
conjugated dienes was observed (Table 4). A positive association between adiponectin 
and TAOC was borderline significant in age- and sex-adjusted analysis. A positive 
association between adiponectin and homocysteine was borderline significant in both 
age- and sex-adjusted and multivariable-adjusted models. 
 
Table 4. Outcomes that remained significantly associated with adiponectin, 
independent of potential confounders. 
 
 
Associations with adiponectin  
 
Age- and sex-adjusted 
 
Multivariable-adjusted 
  β (95% CI) P-value 
 
β (95% CI) P-value 
GSH (µg/mL); n=920 22.61 (10.05; 35.16) 0.00043   20.43 (6.78; 34.09) 0.0034 
log Total GSH (µg/mL); n=921 0.02 (0.01; 0.03) 0.004 
 
0.02 (0.003; 0.03) 0.02 
Conjugated dienes (µmol/L); n=928 -1.62 (-2.33; -0.92) < 0.0001  
 
-0.81 (-1.46; -0.16) 0.015 
log EGF (pg/mL); n=928 -0.07 (-0.14; -0.01) 0.033   -0.08 (-0.15; -0.01) 0.033 
 
Adiponectin was inversely associated with log EGF in age- and sex-adjusted and 
multivariable-adjusted models (Table 4). Further, adiponectin was negatively 
correlated with MCP-1, log E-selectin, and log CRP in age- and sex-adjusted analyses, 
but not in multivariable-adjusted models. 
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Adiponectin remained associated with conjugated dienes, log CRP, and GSH in the 
age- and sex-adjusted models when correcting for multiple testing using the Holm-
Bonferroni method, but no association remained significant in the multivariable-
adjusted models when considering multiple testing (corrected overall critical P-values 
were 0.00263 and 0.00227 respectively). 
 
No effect modification by sex was significant for any of the tested associations. The 
effect of adiponectin on OxLDL was clearly different between individuals with 
previous CVD (β, 12.49; 95% CI, 6.43, 18.55) and individuals without previous CVD 
(β, -3.38; 95% CI, -6.80, 0.04), which was supported by a highly significant interaction 
term of adiponectin and CVD status (P-value=0.00047). A similar pattern was observed 
in analyses stratified by overweight status, where individuals with BMI <25 had an 
inverse association with OxLDL (β, -1.01; 95% CI, -5.83, 3.81), while individuals with 
BMI ≥25 displayed a positive association (β, 1.43; 95% CI, -2.44, 5.29) with a 
significant interaction term (P=0.006). All markers significant in the multivariable-
adjusted model remained significant and with small changes in effect size after 
exclusion of individuals with kidney failure (eGFR < 50 mL/min/1.73m2). Adiponectin 
was not significantly associated with the ratio of reduced and oxidized glutathione in 
age- and sex-adjusted, or multivariable-adjusted models (P-value=0.43 and P-
value=0.36, respectively). The results were also similar when we added total energy 
intake from a 7-day dietary registration to the multivariable model. 
 
 
5.4 Rare Genetic Variation and Adiponectin 
Quantile-quantile (QQ) plots of P-values from the meta-analyses showed no systematic 
deviation from the null, but with a tail of low P-values indicating positive signals. The 
main results are shown in Table 5. 
 
The proportion of rare variants where an individual carried the minor allele within the 
transcript region of ADIPOQ (chromosome 3; b37 position range 186,560,462 - 
186,576,250) was significantly associated with adiponectin levels in our analysis 
defining rare variants based on MAF <5% (Z=-4.86; P-value=1.16×10-6). Three 
independent SNPs (rs115527175, rs17300539, rs113365229) from the ADIPOQ region 
were identified as independent by conditional association tests in a forward selection 
approach. When adjusting the mutational load for independent SNPs around the 
ADIPOQ gene, the mutational load did not remain significant and the signal was only 
driven by the lead SNP rs115527175. 
 
The transcript region of F-box and leucine-rich repeat protein 14 (FBXL14; 
chromosome 12; b37 position range 1,675,159 - 1,703,331) was significantly 
associated with adiponectin when restricting the analysis to coding (Z=4.82; P-
value=1.41×10-6) or non-synonymous variants (Z=5.19; P-value=2.06×10-7). However, 
the most significant analysis, restricted to non-synonymous variants only, included a 
single marker at chr12:1702929. The SNP is a missense variant where a nucleotide 
change from major allele T to minor allele G leads to a shift from asparagine to 
histidine at position 102 (N102H) of the encoded protein. Polyphen-2 classified the 
variant as probably damaging and PANTHER reported a high probability of a 
functional significance. The association between adiponectin and the variant at 
chr12:1702929 was not replicated in IMPROVE (β, -0.04; P-value, 0.87). 
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6 DISCUSSION 
6.1 Adiponectin and the Cardiovascular System 
The main finding of Study I was the inverse association between adiponectin and 
ejection fraction in elderly men, independent of potential confounders including BMI. 
The inverse association was also was also evident in a sub-sample after exclusion of 
individuals with any previously known CVD. Further, our analyses indicated that NT-
proBNP act as a partial mediator of the association of adiponectin with ejection fraction 
as the association was greatly attenuated when adding NT-proBNP to the model, 
although remaining significant. 
 
In contrast to the beneficial cardiometabolic profile of adiponectin,13-16 high 
adiponectin levels have been demonstrated to be associated with mortality and 
hospitalizations in patients with poor cardiac health; mainly heart failure.46, 111 This 
unexpected association could have one or several explanations, including a counter-
active response with a potentially mediating role by natriueric peptides, a confounding 
effect by cardiac cachexia, and adiponectin resistance. 
 
Adiponectin levels have been shown not to predict incident heart failure in healthy 
individuals in ULSAM,112 as well as in the Framingham Heart Study,113 whereas a 
recent prospective study in individuals with prevalent CHD reported that higher 
adiponectin levels were associated with a higher risk of heart failure and death. 
However, after adjustment for CVD severity at baseline, this association was no longer 
significant, which further indicate that the higher levels of adiponectin may be a 
compensatory response to an initial poor cardiac health.114 
 
Based on the previously reported associations of increased adiponectin and BNP 
concentrations with heart failure46-48 or LV dilation,45 we hypothesized that adiponectin 
would be involved in the same cardioregulatory pathway as BNP. Our analyses showed 
that adjustment for NT-proBNP partially attenuated the association between 
adiponectin and ejection fraction. Further, a recent study in asymptomatic older men 
reported a positive association of adiponectin with measures of poor cardiac health, 
which was mainly attenuated by NT-proBNP.115 A potential explanation could be that 
BNP is on the causal pathway by which adiponectin is associated with LV systolic 
function. Previous studies have shown that naturetic peptides exhibit a lipolytic effect 
on human adipose tissue through a cGMP-dependent pathway116-118 that may explain 
the linkage between adiponectin and BNP. Circulating adiponectin has been suggested 
to be a marker of total stimulated adipose tissue triacylglycerol lipolytic capacity in vivo 
in humans.119 Another study demonstrated that infusion of synthetic atrial natriuretic 
peptide (ANP) increased levels of total and high-molecular weight adiponectin in 
patients with heart failure.120 In addition, another study has shown that both ANP and 
BNP increased the adiponectin mRNA expression in a dose-dependent manner, 
mediated through the cGMP-dependent pathway.121 
 
The observation that higher adiponectin is associated with adverse outcomes in 
individuals with prevalent disease, but not the progression of the disease, might also 
suggest that cardiac cachexia, which is seen in many heart failure patients, could lead to 
lower fat mass and consequently higher adiponectin. However, the present study was 
performed in healthy individuals without overt disease, and the inverse association 
between adiponectin and systolic function was also present in a healthier sub-sample 
(after exclusion of all individuals with any prior CVD) and after adjustments for BMI 
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along with other potential confounders. These observations, along with the prior study 
of similarly healthy elderly individuals from Japan,45 suggest that cardiac cachexia is 
unlikely to be the sole reason for the associations of circulating adiponectin, NT-
proBNP and LV systolic function. Nevertheless, it should be noted that the attenuation 
by adding NT-proBNP to the model of the association of adiponectin with ejection 
fraction was even more pronounced in a sub-sample of individuals with prior CVD. 
 
Previous publications have also suggested that increased adiponectin levels in patients 
with poor cardiac health might be a response to adiponectin resistance, where levels are 
increased to counter a poorer response to adiponectin which is dysregulated in the 
diseased state.122 
 
We observed associations of adiponectin with ejection fraction in men, but not in 
women. It has been shown that females have higher levels than males15, 123 and that this 
sex difference in circulating levels of adiponectin might be explained by an inhibitory 
influence of androgens.17, 18 However, the reason for why the association between 
adiponectin and systolic function was present in only men remains to be elucidated. 
 
Previous studies have reported an inverse association between adiponectin and cardiac 
geometry; primarily LV mass,39-43 but also LV hypertrophy assessed by ECG.44 
Consistent with this, adiponectin levels differed significantly between individuals with 
normal geometry and individuals with categories of hypertrophy and/or remodeling, 
adjusted for age and sex (Figure 1). However, further adjustment for BMI rendered this 
association not significant, indicating that BMI is a main confounder of the association 
between adiponectin and cardiac geometry in our samples. 
 
In Study II, higher serum adiponectin was associated with less arterial stiffness (higher 
CCA distensibility) and increased vascular echogenicity (higher IM-GSM and plaque 
GSM), independently of potential confounders including BMI. The results were 
comparable for men and women. The inverse association with arterial stiffness is in line 
with some previous studies,55-57, 124 but not all.52, 58, 59 In 456 elderly men and women, 
high levels of adiponectin were associated with decreased arterial stiffness55 and similar 
results were seen in 98 T2D patients and 116 controls.57 In line with this, low 
adiponectin levels predicted a worsening of arterial stiffness over a one-year period in 
142 postmenopausal women.56 In a more recent case-control study of systemic lupus 
erythematosus, higher adiponectin was associated with less arterial stiffness124 and an 
inverse association was further found between HMW adiponectin and arterial stiffness 
in 269 subjects without a history of cardiovascular disorders.125 
 
The number of plaques in the carotid arteries was not associated with adiponectin, 
which is in line with previous studies.50, 54 In Study II, adiponectin was positively 
associated with plaque GSM in age- and sex-adjusted analysis, as well as multivariable-
adjusted models, indicating that that adiponectin is associated with plaque composition 
rather than plaque presence. However, HMW adiponectin was inversely associated 
with both the presence and extent of coronary plaques, assessed by computed 
tomography angiography in a study of patients with suspected CAD. HMW adiponectin 
was further related to vulnerability characteristics of the coronary plaques.126 To our 
best knowledge, this is the first study investigating in detail the association between 
adiponectin and echogenicity of the vessel wall and arterial plaques in a larger 
population using GSM techniques. Consistent with our finding, a study evaluating an 
ultrasound imaging technique of plaques in 638 women diagnosed with diabetes 
demonstrated that lower levels of adiponectin were associated with echolucent 
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plaques.127 Similarly, a smaller study performed in 66 diabetic and 119 non-diabetic 
patients reported that adiponectin was associated with atherogenic lipoproteins, plaque 
volume and lipid-rich plaques assessed with intravascular ultrasound.128 Plaque 
morphology can be classified according to GSM readings, where plaques with a low 
GSM (echolucent) are characterized by high lipid content and haemorrhages, whereas a 
high GSM (ecogenic) is associated with a fibrous content.129 Our finding that 
adiponectin is positively associated with plaque GSM, indicates that adiponectin 
protects against the ecolucent plaques which is considered to be the most pathological 
form. The ecolucent plaques have been associated with a higher risk of cardiovascular 
events,99 since plaques with a high lipid content are more instable and prone to rupture, 
causing clinical events.130 Similarly, we also found a strong positive association with 
IM-GSM independently of potential confounders. Although not described in previous 
studies, the results of IM-GSM fit into the same context as plaque GSM, since IM-
GSM is closely related to the plaque GSM.97 A low IM-GSM is associated with CVD 
risk factors, such high BMI and low HDL,131 and the echogenicity of apparently 
plaque-free CCA IM complexes measured with the GSM is an significant predictor of 
CVD mortality.132 The association between adiponectin and IM-GSM was independent 
of prior CVD unlike the relation with plaque GSM, which was present only in a 
diseased subsample. One possible explanation could be that individuals in the healthy 
subsample have less diseased vessels, and that the role of adiponectin would be less 
evident than in individuals with more extensive atherosclerosis. 
 
Our analyses showed that levels of adiponectin were positively associated with lower 
fat content in the IM and plaques as well as with higher wall elasticity. Lipid 
accumulation in the vascular wall is a process consisting of several steps; beginning 
with the infiltration of an excess of low-density lipoprotein (LDL) particles, which are 
modified through oxidation and other enzymatic modification, and then further 
internalized by macrophages followed by foam cell formation.133 Adiponectin is 
inversely associated with LDL particle size134 as well as apolipoprotein B or E135 and 
cellular studies have revealed that both globular and full-length adiponectin inhibit the 
generation of reactive oxygen species, thus preventing oxidative stress.136, 137 Also, in 
Study III, adiponectin was associated with higher levels of the principal anti-oxidant 
glutathione and lower levels of lipid peroxidation. Adiponectin suppress the expression 
of macrophage scavenger receptors, reducing the uptake of oxidized LDL and foam cell 
formation.138 Our results in Study III indicate an inverse association between 
adiponectin and oxidized LDL in individuals without previous CVD, whereas the 
opposite was observed for individuals with CVD. Adiponectin also suppress the growth 
of macrophage progenitor cells and mature macrophage function;139 thus, possibly 
restraining the formation of foam cells and early atherosclerosis. An in vivo study in 
mice showed that adiponectin attenuated neointimal thickening and an in vitro 
experiment further demonstrated that adiponectin suppressed the proliferation and 
migration of smooth muscle cells, stimulated by HB-EGF.140 Also, HDL is postulated 
to play a protecting role against atherosclerosis by the removal of excess cholesterol via 
the liver.141 Adiponectin has been demonstrated to increase the HDL assembly in the 
liver; thus providing another complementary mechanism linking adiponectin to 
atherosclerosis.142 
 
The distensibility of the cell wall is associated with an increase of collegenous material 
and degeneration of elastic fibers.143 However, the association between adiponectin and 
changes in the vascular matrix remains to be fully examined. Lower insulin sensitivity 
is associated with increased stiffness,144 thus providing another possible mechanism 
linking adiponectin to CCA distensibility, since adiponectin is inversely associated with 
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T2D and insulin resistance.145 Further, the stiffness of the CCA is related to the 
presence of atherosclerosis;146 thus the mechanisms described above, linking 
adiponectin to vascular morphology, might share common pathways with mechanisms 
linking adiponectin to vascular function. 
 
 
6.2 Adiponectin, Oxidative Stress, and Inflammation 
We found that higher levels of adiponectin were associated with higher levels of 
glutathione (GSH and total GSH), lower levels of lipid peroxidation products 
(conjugated dienes), and lower levels of the growth factor EGF. 
 
A few previous studies have investigated the association between adiponectin and the 
ratio of reduced and oxidized glutathione in selected materials with small sample sizes. 
In 12 obese psoriasis patients, an inverse correlation between adiponectin and the ratio 
of GSSG/GSH was reported62 and similarly adiponectin correlated positively with the 
GSG/GSSG ratio in 120 subjects with or without diabetes and with or without non-
alcoholic fatty liver disease.63 Further, adiponectin was shown to restore the 
GSH/GSSG ratio after it was reduced when treating HepG2 cells with palmitate.63 We 
did not find a significant association with the GSH/GSSG ratio, but a strong association 
with absolute levels of GSH and TGSH. 
 
In line with our results, several studies have reported that lower adiponectin associates 
with increased levels of lipid peroxidation byproducts,8, 64-66 but not all.67 A negative 
correlation between adiponectin and 8-epi-PGF2α was found in 105 Japanese men and 
women without diabetes, CVD or renal disease.65 Further, 8-epi-PGF2α was inversely 
correlated with adiponectin in 259 Japanese men and women with normal glucose 
tolerance, impaired glucose tolerance or diabetes; however, not significantly when 
adjusting for the full set of confounders.66 No association with urinary 8-epi-PGF2α 
was found in 76 non-diabetic, hypercholesterolemic patients.67 Moreover, an inverse 
association between adiponectin and thiobarbituric acid-reacting substance (TBARS), 
as well as urinary 8-epi-PGF2α was found in 140 Japanese individuals8 and an inverse 
association of adiponectin with TBARS was reported in 1,178 Japanese men.64 
However, no significant association between one-year change in adiponectin and one-
year change in TBARS was found.64 
 
Adiponectin can both affect and be affected by the oxidative environment. Previous 
studies have suggested that the oxidative environment could influence adiponectin 
secretion and assembly. One study in rats suggested that adiponectin secretion might be 
decreased in response to an oxidative environment147 and an in vitro study indicated 
that adiponectin oligomerization is dependent on the redox environment.148 Strong 
correlations were found between the mRNA expression levels of the adiponectin 
receptors (ADIPOR1 and ADIPOR2) and glutathione peroxidase-1 in 60 morbidly 
obese patients with non-alcoholic fatty liver disease149 suggesting shared/linked factors 
regulating gene expression. Further, adiponectin has been to shown to protect against 
elevated oxidative stress levels. A study showed that addition of adiponectin 
maintained normal oxidative stress levels and GSH levels in cells exposed to 
OxLDL.150 An in vitro experiment revealed that hypoxia-induced lipid peroxidation in 
cells was completely attenuated after treatment with adiponectin and that treatment 
with adiponectin partly attenuated hypoxia-induced loss of intracellular GSH. Further, 
in an in vivo experiment, adiponectin-overexpressing transgenic mice had significantly 
lower levels of lipid peroxidation products (hypoxia-induced) compared with wild-type 
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mice. The levels of GSH were also higher in the lungs of the transgenic mice compared 
with wild-type.151 
 
We found an inverse association between adiponectin and EGF. A previous study has 
found an inverse association between mRNA expression of adiponectin and heparin-
binding epidermal growth factor-like growth factor (HB-EGF), which is structurally 
similar to EGF. Further, the EGF receptor (EGFR) activation and transverse aortic 
constriction-induced cardiac hypertrophy was higher in adiponectin knockout mice 
compared with wild-type, and treatment with adiponectin reduced the EGFR activity.152 
In an in vitro experiment, adiponectin suppressed the proliferation and migration of 
smooth muscle cells, stimulated by HB-EGF. Adiponectin also attenuated DNA 
synthesis induced by EGF.140 
 
Our results indicated an inverse association between adiponectin and OxLDL in 
individuals without prior CVD, whereas somewhat unexpectedly, a positive association 
was observed in individuals with prior CVD. A similar pattern was seen for normal-
weight versus overweight individuals. Previous large studies have indicated an inverse 
association between adiponectin and OxLDL, including one study of 2,985 
individuals153 and another study of 1,309 postmenopausal women without coronary 
artery disease or diabetes.154 However, in contrast, a significant positive association 
was found in 106 pregnant women, but not in matched non-pregnant women.155 As 
previously discussed, some studies have found that adiponectin is associated with 
worse cardiovascular outcomes and have suggested that this might be part of a 
compensatory mechanism in response to poor CVD health.114 The observed positive 
association between adiponectin and OxLDL among those with prior CVD, could 
potentially be explained by a similar phenomenon, where the increased levels represent 
a counter-active response to the diseased state. 
 
 
6.3 Genetic Determinants of Adiponectin 
Previous GWA studies investigating associations between common genetic variants 
and adiponectin levels have identified strong signals, mainly at ADIPOQ,34, 82, 83 
ARL15,34, 83 and CDH13.34, 36-38 Some studies have investigated rare variation in 
selected regions after re-sequencing of ADIPOQ81 and analysis of rare haplotypes at 
KNG1-ADIPOQ,38 but rare variation across the entire genome in relation to 
adiponectin levels remains an unexplored path. To our best knowledge, no previous 
studies have investigated the association between circulating adiponectin levels and 
the proportion of rare alleles within a gene carried by an individual on a genome-wide 
scale. In our analysis, we identified two potential regions where the proportion of 
minor alleles at rare variants was associated with adiponectin after taking multiple 
testing into account – ADIPOQ and FBXL14. 
 
In analyses including all markers, the transcript region of ADIPOQ was significantly 
associated with lower levels of adiponectin. However, this mutational burden test 
signal was explained by one single variant in ADIPOQ, i.e. the burden test signal was 
correlated with an ADIPOQ SNP and we found no evidence of a burden test signal 
once we accounted for this SNP in the regression model. This SNP was identified in a 
standard association test, so in this case, the burden test did not add anything new in 
addition to a regular SNP-based test. 
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The transcript region of FBXL14 was significantly associated with higher adiponectin 
levels when restricting the analysis to coding or non-synonymous markers, which 
appeared to be driven by a single non-synonymous marker at chr12:1702929. This SNP 
is a missense variant where the rare allele has a potentially damaging effect on the 
protein. However, since this variant was not replicated in the IMPROVE study, the 
results should be interpreted with caution. The lack of replication could potentially 
indicate a false positive finding, but could also be due to low statistical power or high 
between-study heterogeneity given that IMPROVE is a study of high-risk individuals 
of CVD whereas the discovery samples are population-based. If the variant is a true 
positive finding, it remains to be established through which pathways this variant is 
associated with adiponectin levels; however, the presence of ADIPOR2 in the region is 
intriguing. 
 
ADIPOQ has the most apparent connection with adiponectin levels out of the two genes 
identified in the present study. We have not found a connection between adiponectin 
and the gene product of FBXL14. However, interestingly, FBXL14 lies upstream of the 
adiponectin receptor 2, which makes this region an interesting target for further 
analyses. ADIPOR2 encodes the Adiponectin receptor 2 which is an intermediate-
affinity receptor for full-length adiponectin that seems affect peroxisome proliferator-
activated receptor-α signalling pathways and fatty acid oxidation.30, 31 No prior GWA 
studies have reported an association of the ADIPOR2 locus with adiponectin levels. 
Even if we did not replicate this finding in IMPROVE, it seems likely that the finding 
is a true positive given the high probability of a biological link between circulating 
adiponectin and the genetic region around an adiponectin receptor. 
 
 
6.4 Strengths and Limitations 
The main strengths of this thesis include the two large community-based samples of 
elderly with detailed phenotypes representing different aspects of the CVD process. 
These individuals are well-characterized which also allows for adjustment for relevant 
confounding factors. In addition, with our dense genotype data we can investigate the 
impact of rare genetic variation on adiponectin levels, which has not been studied in 
detail previously. 
 
There are several limitations that should be mentioned. First, adiponectin aggregates 
into several oligomeric forms, and this thesis focuses on total adiponectin, i.e. the sum 
of all forms rather than separate measures for each fraction. Some studies have 
indicated differences in biological activity between different forms of adiponectin with 
regard to metabolic abnormalities.28, 29 However, this remains to be fully established 
and yet other studies have found similar associations of total adiponectin and the HMW 
fraction (which are highly correlated) with for example T2D.156 Second, since our 
samples include elderly individuals of Northern European ancestry, the generalizability 
to other age groups and ethnicities is unknown. However, it is expected that the lower 
variation in age and ethnic background of our studies provide a high internal validity 
and reduce the effect of confounding with regard to these factors. Third, we cannot 
assess causality in Study I-III due the cross-sectional and observational design of the 
studies, nor can it be determined if the outcomes are related to the longitudinal tracking 
of adiponectin concentrations. Fourth, in Study I, ejection fraction was measured 
according to the Teichholz formula using M-mode in both cohorts. This way to 
evaluate ejection fraction has its known limitations, since it does not take into 
consideration dyskinesia in other segments than those included in the M-mode 
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recording. Despite this limitation, this way of measuring ejection fraction is still used 
very frequently in the clinical setting, a substantial part of the literature regarding the 
predictive power of ejection fraction, and inclusion criteria in landmark heart failure 
treatment trials are based on this method. Fifth, the sample sizes in Study IV were 
relatively modest to investigate the impact of rare genetic variants where few 
individuals carry the minor allele, meaning that several findings that did not reach 
multiple testing-corrected significance can represent true associations with adiponectin, 
and may merit further exploration in future studies. Sixth, in Study IV, our replication 
stage was not ideally designed given the limited sample size of the replication sample 
and the fact that we genotyped just one SNP instead of sequencing the whole region (to 
find other rare variants that could contribute to the mutational load). Finally, the 
samples were stored in -70°C for 1-3 years (PIVUS) and 11±2 years (ULSAM) before 
being analyzed. However, at the time of collection, the samples were ideally treated to 
limit any influence on stability of samples. The effect of frozen storage on adiponectin 
levels has to our best knowledge been investigated under a maximum of 30 months, 
reporting no discernible effect of mean plasma adiponectin levels.157 We are not aware 
of any other studies with longer follow-up, but most peptide hormones has been shown 
to be fairly stable, some peptides even during long-term storage up to 25 years.158 
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7 CONCLUSIONS 
I. In our two community-based samples of elderly, adiponectin concentrations 
were inversely associated with ejection fraction in men, even after adjustment 
for potential confounders including BMI. These associations were partially 
attenuated by additional adjustment for NT-proBNP, indicating that adiponectin 
may be associated with depressed LV systolic function through pathways 
shared with natriuretic peptides; potentially as a counter-active response to poor 
cardiac health. Further studies are required to establish the biological pathways 
linking adiponectin, natriuretic peptides and cardiac function. 
 
II. Higher circulating adiponectin was associated with a lower fat content in the 
vessel wall and plaques. Adiponectin was also positively associated with higher 
vessel wall distensibility; the distensibility is a measure of wall elasticity, and a 
higher value is equivalent to lower arterial stiffness. Together, these findings 
imply that adiponectin is associated with less arterial pathology. The pathways 
linking adiponectin with higher vessel echogenicity and elasticity need to be 
further investigated using other study designs. 
 
III. Adiponectin levels were positively associated with the primary anti-oxidant 
glutathione (GSH and TGSH) and negatively associated with products of lipid 
peroxidation (conjugated dienes). Together these associations suggest that 
adiponectin is associated with a more beneficial oxidative stress profile, 
potentially through shared pathways. Further studies are needed to investigate 
whether anti-oxidative effects may be a mechanism linking adiponectin with 
type 2 diabetes and/or cardiovascular disease. 
 
IV. Our results indicated that individuals who carry a larger proportion of minor 
alleles at rare variants within ADIPOQ have on average lower levels of 
adiponectin, but this signal was driven by one SNP in the gene. Further, a 
significant positive association was observed in analyses including a single non-
synonymous marker at chr12:1702929 in a gene upstream of ADIPOR2. If 
replicated in independent samples, our results could be of importance for the 
understanding of adiponectin biology. 
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8 FUTURE PERSPECTIVES 
8.1 Study Design 
Many of the epidemiological studies in the adiponectin research field as well as in this 
thesis are of cross-sectional design and causality cannot be assessed. Even though these 
studies provide important information regarding in which pathways adiponectin might 
be involved, large longitudinal studies are needed since they offer the possibility to 
investigate changes in adiponectin as well as the outcome over time, which is needed to 
elucidate the causal role of adiponectin in different cardiometabolic disorders. In 
addition, Mendelian randomization studies should also be mentioned as an interesting 
cross-sectional alternative to investigate the causal role of adiponectin in the 
development of subclinical and overt disease. 
 
Some previous studies have indicated that different oligomeric forms of adiponectin 
elicit different biological effects. This remains to be fully established, but future studies 
should aim at measuring each fraction to investigate this possibility. Standardization of 
assay procedures to measure the different forms of adiponectin would be warranted. 
 
To further study the influence of genetic variation on adiponectin levels, larger sample 
sizes are merited. A recent large meta-analysis including a total of 45,891 individuals in 
the ADIPOGen consortium confirmed known adiponectin loci and identified several 
novel loci,34 and this type of effort could be expanded to study rare genetic variants in 
relation to adiponectin. 
 
 
8.2 Adiponectin as a Biomarker and Utility in Risk Prediction 
Adiponectin has several attractive features as a biomarker such as a high levels in 
plasma23 and high stability.159 However, there are also several problems associated with 
the use of adiponectin as a biomarker. First, given that the mean levels differs with 
regard to gender15 and ethnicity,160, 161 more data is needed to find reference values for 
what constitutes a normal adiponectin level in the different subgroups. This is further 
complicated by the fact that adiponectin, through dysregulation or as part of a 
compensatory mechanism, is increased in conditions such as heart failure; hence, high 
adiponectin levels are not always associated with a healthy profile. Adiponectin is 
associated with a mostly beneficial health profile, e.g. an inverse relation to BMI,12 
T2D,13 hypertension,14 and triglycerides.15 However, given the high correlation 
between adiponectin and several CVD risk factors, it remains to be established how 
much adiponectin can add to established risk factors in the prediction of CVD risk in a 
clinical setting. 
 
 
8.3 New Biological Pathways and Pharmaceutical Targets 
Several pathways linked to the regulation of adiponectin, as well as adiponectin 
signaling have been established or suggested, but more research is needed. In order to 
fully elucidate the signal transduction and downstream effect after adiponectin binds to 
its receptors, a targeted approach can be used to study selected pathways in vitro and in 
vivo. Further, an untargeted approach, using techniques such transcriptomics, 
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proteomics, and metabolomics can give further hints about the intra- and extra-cellular 
pathways that are related to adiponectin. 
 
Administering adiponectin as a drug has proven difficult,162 but agents that increase 
adiponectin levels as well as agonists targeting the adiponectin receptors might offer a 
solution. Research about adiponectin as a pharmaceutical agent is in early development 
and it can be mentioned that an adiponectin-based peptide compound acting as an 
adiponectin receptor agonist in cancer cells was recently developed.162 
  
 32 
9 ACKNOWLEDGEMENTS 
 
Erik Ingelsson, my main-supervisor – thank you for your support and encouragement 
during my PhD. You have been such a flexible supervisor, always been there to help, 
and you have given me many great research opportunities. I cannot thank you enough 
and could not have wished for a better supervisor! 
 
Lars Lind, my co-supervisor – thank you for all your help with my manuscripts and for 
sharing your expertise about cardiovascular research. 
 
I would also like to thank: 
 
All my co-authors – Allan Flyvbjerg, Anders Hamsten, Andrew Morris, Anubha 
Mahajan, Björn Zethelius, Cecilia Lindgren, Erik Ingelsson, Johannes Hulthe, Lars 
Lind, Mihkel Zilmer, Per Venge, Rona Strawbridge, and Stefan Söderberg. 
 
All members of our research group – Andrea Ganna, Ci Song, He Gao, Jitender Kumar, 
Katherine Kasiman, Marcel den Hoed, Sara Hägg, and Tove Fall. 
 
Everyone at WTCHG, Oxford University – Andrew Morris, Anubha Mahajan, Cecilia 
Lindgren, Mark McCarthy, Momoko Horikoshi, Reedik Mägi, and all others. 
 
Past and current members of the Heart and Mind group – Adina Feldman, Iffat 
Rahman, Jonathan Prince, Lotte Gerritsen, Mun-Gwan Hong, Nancy Pedersen, Patrik 
Magnusson, and all others. 
 
Everyone at MEB – Alexander Ploner, Camilla Ahlqvist, Ove Strind, Rikard Öberg, 
Zack Yusof, and all others. 
 
Many thanks to all participants in the PIVUS and ULSAM study whose data this thesis 
is based upon. 
 
Last but definitely not least, I would like to thank my friends and family for always 
being there for me. 
   33 
10 REFERENCES 
1. Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease 
prevention and control. Geneva: World Health Organisation; 2011. 
2. Heidenreich PA, et al. Forecasting the future of cardiovascular disease in the 
United States: a policy statement from the American Heart Association. 
Circulation. 2011;123:933-944 
3. Nichols M, Townsend N, Scarborough P, Luengo-Fernandez R, Leal J, Gray A, 
Rayner M. European Cardiovascular Disease Statistics 2012. Brussels: 
European Heart Network and European Society of Cardiology; 2012. 
4. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197-1209 
5. Iyer A, Fairlie DP, Prins JB, Hammock BD, Brown L. Inflammatory lipid 
mediators in adipocyte function and obesity. Nat Rev Endocrinol. 2010;6:71-82 
6. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, 
Jr. Obesity is associated with macrophage accumulation in adipose tissue. J 
Clin Invest. 2003;112:1796-1808 
7. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose 
tissue. J Clin Invest. 2003;112:1785-1788 
8. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, 
Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative 
stress in obesity and its impact on metabolic syndrome. J Clin Invest. 
2004;114:1752-1761 
9. Keaney JF, Jr., Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, 
Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic 
oxidative stress: clinical correlates of oxidative stress in the Framingham Study. 
Arterioscler Thromb Vasc Biol. 2003;23:434-439 
10. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, 
Arita Y, Kihara S, Matsuzawa Y. Role of adipocytokines on the pathogenesis of 
atherosclerosis in visceral obesity. Intern Med. 1999;38:202-206 
11. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. 
cDNA cloning and expression of a novel adipose specific collagen-like factor, 
apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res 
Commun. 1996;221:286-289 
12. Arita Y, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, 
in obesity. Biochem Biophys Res Commun. 1999;257:79-83 
13. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 
diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179-188 
14. Iwashima Y, et al. Hypoadiponectinemia is an independent risk factor for 
hypertension. Hypertension. 2004;43:1318-1323 
15. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff 
BM, Knopp RH, Brunzell JD, Kahn SE. Relationship of adiponectin to body fat 
distribution, insulin sensitivity and plasma lipoproteins: evidence for 
independent roles of age and sex. Diabetologia. 2003;46:459-469 
16. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma 
adiponectin levels and risk of myocardial infarction in men. JAMA : the journal 
of the American Medical Association. 2004;291:1730-1737 
17. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, 
Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, 
Funahashi T, Matsuzawa Y. Androgens decrease plasma adiponectin, an 
insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51:2734-2741 
 34 
18. Page ST, Herbst KL, Amory JK, Coviello AD, Anawalt BD, Matsumoto AM, 
Bremner WJ. Testosterone administration suppresses adiponectin levels in men. 
J Androl. 2005;26:85-92 
19. Isobe T, Saitoh S, Takagi S, Takeuchi H, Chiba Y, Katoh N, Shimamoto K. 
Influence of gender, age and renal function on plasma adiponectin level: the 
Tanno and Sobetsu study. European journal of endocrinology / European 
Federation of Endocrine Societies. 2005;153:91-98 
20. Wanders D, Plaisance EP, Judd RL. Lipid-lowering drugs and circulating 
adiponectin. Vitam Horm. 2012;90:341-374 
21. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, 
Olefsky JM. The effect of thiazolidinediones on plasma adiponectin levels in 
normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-2974 
22. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in 
cancer: a review of current evidence. Endocr Rev. 2012;33:547-594 
23. Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of 
adiponectin. Med Mol Morphol. 2007;40:55-67 
24. Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of 
adiponectin: mechanisms and functional implications. Biochem J. 
2008;409:623-633 
25. Innamorati G, Bianchi E, Whang MI. An intracellular role for the C1q-globular 
domain. Cell Signal. 2006;18:761-770 
26. Waki H, Yamauchi T, Kamon J, Kita S, Ito Y, Hada Y, Uchida S, Tsuchida A, 
Takekawa S, Kadowaki T. Generation of globular fragment of adiponectin by 
leukocyte elastase secreted by monocytic cell line THP-1. Endocrinology. 
2005;146:790-796 
27. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, Hara K, Hada Y, 
Vasseur F, Froguel P, Kimura S, Nagai R, Kadowaki T. Impaired 
multimerization of human adiponectin mutants associated with diabetes. 
Molecular structure and multimer formation of adiponectin. The Journal of 
biological chemistry. 2003;278:40352-40363 
28. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, Imai Y, 
Nagai R, Kadowaki T. Measurement of the high-molecular weight form of 
adiponectin in plasma is useful for the prediction of insulin resistance and 
metabolic syndrome. Diabetes Care. 2006;29:1357-1362 
29. Pajvani UB, et al. Complex distribution, not absolute amount of adiponectin, 
correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J 
Biol Chem. 2004;279:12152-12162 
30. Yamauchi T, et al. Cloning of adiponectin receptors that mediate antidiabetic 
metabolic effects. Nature. 2003;423:762-769 
31. Yamauchi T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes 
abrogation of adiponectin binding and metabolic actions. Nature medicine. 
2007;13:332-339 
32. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a 
receptor for hexameric and high-molecular-weight forms of 
Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004;101:10308-10313 
33. Lee MH, Klein RL, El-Shewy HM, Luttrell DK, Luttrell LM. The adiponectin 
receptors AdipoR1 and AdipoR2 activate ERK1/2 through a Src/Ras-dependent 
pathway and stimulate cell growth. Biochemistry. 2008;47:11682-11692 
34. Dastani Z, et al. Novel loci for adiponectin levels and their influence on type 2 
diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 
individuals. PLoS genetics. 2012;8:e1002607 
   35 
35. Ling H, Waterworth DM, Stirnadel HA, Pollin TI, Barter PJ, Kesaniemi YA, 
Mahley RW, McPherson R, Waeber G, Bersot TP, Cohen JC, Grundy SM, 
Mooser VE, Mitchell BD. Genome-wide linkage and association analyses to 
identify genes influencing adiponectin levels: the GEMS Study. Obesity (Silver 
Spring). 2009;17:737-744 
36. Morisaki H, Yamanaka I, Iwai N, Miyamoto Y, Kokubo Y, Okamura T, 
Okayama A, Morisaki T. CDH13 gene coding T-cadherin influences variations 
in plasma adiponectin levels in the Japanese population. Hum Mutat. 
2012;33:402-410 
37. Jee SH, et al. Adiponectin concentrations: a genome-wide association study. Am 
J Hum Genet. 2010;87:545-552 
38. Wu Y, Li Y, Lange EM, Croteau-Chonka DC, Kuzawa CW, McDade TW, Qin 
L, Curocichin G, Borja JB, Lange LA, Adair LS, Mohlke KL. Genome-wide 
association study for adiponectin levels in Filipino women identifies CDH13 
and a novel uncommon haplotype at KNG1-ADIPOQ. Hum Mol Genet. 
2010;19:4955-4964 
39. Ebinc H, Ebinc FA, Ozkurt ZN, Dogru MT, Tulmac M, Yilmaz M, Caglayan 
O. Impact of adiponectin on left ventricular mass index in non-complicated 
obese subjects. Endocr J. 2008;55:523-528 
40. Ybarra J, Pou JM, Planas F, Ballesta-Lopez C, Echevarne F, Romeo JH, 
Navarro-Lopez F. Correlation between insulin resistance surrogates and 
echocardiographic findings in asymptomatic patients with morbid obesity: a 
cross-sectional study. Endocr Pract. 2007;13:590-600 
41. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma 
adiponectin, hypertension, left ventricular diastolic function and left ventricular 
mass index. Blood Press. 2004;13:236-242 
42. Top C, Sahan B, Onde ME. The relationship between left ventricular mass 
index and insulin sensitivity, postprandial glycaemia, and fasting serum 
triglyceride and adiponection levels in patients with type 2 diabetes. J Int Med 
Res. 2007;35:909-916 
43. Kozakova M, Muscelli E, Flyvbjerg A, Frystyk J, Morizzo C, Palombo C, 
Ferrannini E. Adiponectin and left ventricular structure and function in healthy 
adults. J Clin Endocrinol Metab. 2008;93:2811-2818 
44. Mitsuhashi H, Yatsuya H, Tamakoshi K, Matsushita K, Otsuka R, Wada K, 
Sugiura K, Takefuji S, Hotta Y, Kondo T, Murohara T, Toyoshima H. 
Adiponectin level and left ventricular hypertrophy in Japanese men. 
Hypertension. 2007;49:1448-1454 
45. Ohara T, Kim J, Asakura M, Asanuma H, Nakatani S, Hashimura K, Kanzaki 
H, Funahashi T, Tomoike H, Kitakaze M. Plasma adiponectin is associated with 
plasma brain natriuretic peptide and cardiac function in healthy subjects. 
Hypertens Res. 2008;31:825-831 
46. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, 
Hildebrandt P. Plasma adiponectin, body mass index, and mortality in patients 
with chronic heart failure. Circulation. 2005;112:1756-1762 
47. Haugen E, Furukawa Y, Isic A, Fu M. Increased adiponectin level in parallel 
with increased NT-pro BNP in patients with severe heart failure in the elderly: 
A hospital cohort study. Int J Cardiol. 2008;125:216-219 
48. Tamura T, Furukawa Y, Taniguchi R, Sato Y, Ono K, Horiuchi H, Nakagawa 
Y, Kita T, Kimura T. Serum adiponectin level as an independent predictor of 
mortality in patients with congestive heart failure. Circ J. 2007;71:623-630 
49. Behre CJ, Brohall G, Hulthe J, Wikstrand J, Fagerberg B. Are serum 
adiponectin concentrations in a population sample of 64-year-old Caucasian 
 36 
women with varying glucose tolerance associated with ultrasound-assessed 
atherosclerosis? J Intern Med. 2006;260:238-244 
50. Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. 
Plasma adiponectin levels and sonographic phenotypes of subclinical carotid 
artery atherosclerosis: data from the SAPHIR Study. Stroke. 2005;36:2577-
2582 
51. Karakitsos D, De Groot E, Patrianakos AP, Parthenakis F, Boletis J, Karabinis 
A, Kyriazis J, Vardas P, Daphnis E. Adiponectin and cardiovascular remodeling 
in end-stage renal disease and co-morbid diabetes mellitus. Am J Nephrol. 
2006;26:340-347 
52. Nishida M, Moriyama T, Ishii K, Takashima S, Yoshizaki K, Sugita Y, 
Yamauchi-Takihara K. Effects of IL-6, adiponectin, CRP and metabolic 
syndrome on subclinical atherosclerosis. Clin Chim Acta. 2007;384:99-104 
53. Nilsson PM, Engstrom G, Hedblad B, Frystyk J, Persson MM, Berglund G, 
Flyvbjerg A. Plasma adiponectin levels in relation to carotid intima media 
thickness and markers of insulin resistance. Arterioscler Thromb Vasc Biol. 
2006;26:2758-2762 
54. Kiris I, Tekin I, Yesildag A, Vural H, Oyar O, Sirin B, Okutan H, Ibrisim E. 
Inverse relationship between adiponectin levels and subclinical carotid 
atherosclerosis in patients undergoing coronary artery bypass grafting. Int Heart 
J. 2006;47:855-866 
55. Snijder MB, Flyvbjerg A, Stehouwer CD, Frystyk J, Henry RM, Seidell JC, 
Heine RJ, Dekker JM. Relationship of adiposity with arterial stiffness as 
mediated by adiponectin in older men and women: the Hoorn Study. Eur J 
Endocrinol. 2009;160:387-395 
56. Stork S, Bots ML, Angerer P, von Schacky C, Grobbee DE, Angermann CE, 
Seufert J. Low levels of adiponectin predict worsening of arterial morphology 
and function. Atherosclerosis. 2007;194:e147-153 
57. Araki T, Emoto M, Yokoyama H, Maeno T, Hatsuda S, Mori K, Koyama H, 
Shoji T, Inaba M, Nishizawa Y. The association of plasma adiponectin level 
with carotid arterial stiffness. Metabolism. 2006;55:587-592 
58. Mahmud A, Feely J. Adiponectin and arterial stiffness. Am J Hypertens. 
2005;18:1543-1548 
59. Kojima S, Funahashi T, Maruyoshi H, Honda O, Sugiyama S, Kawano H, 
Soejima H, Miyamoto S, Hokamaki J, Sakamoto T, Yoshimura M, Kitagawa A, 
Matsuzawa Y, Ogawa H. Levels of the adipocyte-derived plasma protein, 
adiponectin, have a close relationship with atheroma. Thromb Res. 
2005;115:483-490 
60. Torigoe M, Matsui H, Ogawa Y, Murakami H, Murakami R, Cheng XW, 
Numaguchi Y, Murohara T, Okumura K. Impact of the high-molecular-weight 
form of adiponectin on endothelial function in healthy young men. Clin 
Endocrinol (Oxf). 2007;67:276-281 
61. Ouchi N, et al. Association of hypoadiponectinemia with impaired 
vasoreactivity. Hypertension. 2003;42:231-234 
62. Kaur S, Zilmer K, Kairane C, Kals M, Zilmer M. Clear differences in 
adiponectin level and glutathione redox status revealed in obese and normal-
weight patients with psoriasis. Br J Dermatol. 2008;159:1364-1367 
63. Sandhya N, Gokulakrishnan K, Ravikumar R, Mohan V, Balasubramanyam M. 
Association of hypoadiponectinemia with hypoglutathionemia in NAFLD 
subjects with and without type 2 diabetes. Dis Markers. 2010;29:213-221 
64. Okauchi Y, Kishida K, Funahashi T, Noguchi M, Ogawa T, Okita K, Iwahashi 
H, Ohira T, Imagawa A, Nakamura T, Shimomura I. Cross-sectional and 
   37 
longitudinal study of association between circulating thiobarbituric acid-
reacting substance levels and clinicobiochemical parameters in 1,178 middle-
aged Japanese men - the Amagasaki Visceral Fat Study. Nutr Metab (Lond). 
2011;8:82 
65. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic 
oxidative stress is associated with visceral fat accumulation and the metabolic 
syndrome. Circ J. 2006;70:1437-1442 
66. Nakanishi S, Yamane K, Kamei N, Nojima H, Okubo M, Kohno N. A 
protective effect of adiponectin against oxidative stress in Japanese Americans: 
the association between adiponectin or leptin and urinary isoprostane. 
Metabolism. 2005;54:194-199 
67. Shin MJ, Lee JH, Jang Y, Park E, Oh J, Chung JH, Chung N. Insulin resistance, 
adipokines, and oxidative stress in nondiabetic, hypercholesterolemic patients: 
leptin as an 8-epi-prostaglandin F2alpha determinant. Metabolism. 
2006;55:918-922 
68. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. 
Biochem J. 2010;425:41-52 
69. Ohashi K, Ouchi N, Matsuzawa Y. Anti-inflammatory and anti-atherogenic 
properties of adiponectin. Biochimie. 2012;94:2137-2142 
70. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O. What's 
new in our understanding of the role of adipokines in rheumatic diseases? Nat 
Rev Rheumatol. 2011;7:528-536 
71. Yuan J, Liu W, Liu ZL, Li N. cDNA cloning, genomic structure, chromosomal 
mapping and expression analysis of ADIPOQ (adiponectin) in chicken. 
Cytogenet Genome Res. 2006;112:148-151 
72. Comuzzie AG, Funahashi T, Sonnenberg G, Martin LJ, Jacob HJ, Black AE, 
Maas D, Takahashi M, Kihara S, Tanaka S, Matsuzawa Y, Blangero J, Cohen 
D, Kissebah A. The genetic basis of plasma variation in adiponectin, a global 
endophenotype for obesity and the metabolic syndrome. J Clin Endocrinol 
Metab. 2001;86:4321-4325 
73. Chuang LM, Chiu YF, Sheu WH, Hung YJ, Ho LT, Grove J, Rodriguez B, 
Quertermous T, Chen YD, Hsiung CA, Tai TY. Biethnic comparisons of 
autosomal genomic scan for loci linked to plasma adiponectin in populations of 
Chinese and Japanese origin. J Clin Endocrinol Metab. 2004;89:5772-5778 
74. Lindsay RS, Funahashi T, Krakoff J, Matsuzawa Y, Tanaka S, Kobes S, 
Bennett PH, Tataranni PA, Knowler WC, Hanson RL. Genome-wide linkage 
analysis of serum adiponectin in the Pima Indian population. Diabetes. 
2003;52:2419-2425 
75. Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS, O'Donnell 
CJ, Cupples LA, Meigs JB. Common variants in the adiponectin gene 
(ADIPOQ) associated with plasma adiponectin levels, type 2 diabetes, and 
diabetes-related quantitative traits: the Framingham Offspring Study. Diabetes. 
2008;57:3353-3359 
76. Mousavinasab F, Tahtinen T, Jokelainen J, Koskela P, Vanhala M, Oikarinen J, 
Keinanen-Kiukaanniemi S, Laakso M. Common polymorphisms (single-
nucleotide polymorphisms SNP+45 and SNP+276) of the adiponectin gene 
regulate serum adiponectin concentrations and blood pressure in young Finnish 
men. Mol Genet Metab. 2006;87:147-151 
77. Berthier MT, Houde A, Cote M, Paradis AM, Mauriege P, Bergeron J, Gaudet 
D, Despres JP, Vohl MC. Impact of adiponectin gene polymorphisms on 
plasma lipoprotein and adiponectin concentrations of viscerally obese men. J 
Lipid Res. 2005;46:237-244 
 38 
78. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, 
Shimomura I, Hotta K, Kuriyama H, Kihara S, Nakamura T, Yamashita S, 
Funahashi T, Matsuzawa Y. Genomic structure and mutations in adipose-
specific gene, adiponectin. Int J Obes Relat Metab Disord. 2000;24:861-868 
79. Vasseur F, et al. Single-nucleotide polymorphism haplotypes in the both 
proximal promoter and exon 3 of the APM1 gene modulate adipocyte-secreted 
adiponectin hormone levels and contribute to the genetic risk for type 2 diabetes 
in French Caucasians. Hum Mol Genet. 2002;11:2607-2614 
80. Tanimura D, et al. Relation of a common variant of the adiponectin gene to 
serum adiponectin concentration and metabolic traits in an aged Japanese 
population. Eur J Hum Genet. 2011;19:262-269 
81. Warren LL, et al. Deep Resequencing Unveils Genetic Architecture of 
ADIPOQ and Identifies a Novel Low-Frequency Variant Strongly Associated 
With Adiponectin Variation. Diabetes. 2012 
82. Heid IM, et al. Clear detection of ADIPOQ locus as the major gene for plasma 
adiponectin: results of genome-wide association analyses including 4659 
European individuals. Atherosclerosis. 2010;208:412-420 
83. Richards JB, et al. A genome-wide association study reveals variants in ARL15 
that influence adiponectin levels. PLoS Genet. 2009;5:e1000768 
84. Croteau-Chonka DC, Wu Y, Li Y, Fogarty MP, Lange LA, Kuzawa CW, 
McDade TW, Borja JB, Luo J, AbdelBaky O, Combs TP, Adair LS, Lange EM, 
Mohlke KL. Population-specific coding variant underlies genome-wide 
association with adiponectin level. Hum Mol Genet. 2012;21:463-471 
85. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different 
methods to evaluate endothelium-dependent vasodilation in the elderly: the 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. 
Arterioscler Thromb Vasc Biol. 2005;25:2368-2375 
86. Hedstrand H. A study of middle-aged men with particular reference to risk 
factors for cardiovascular disease. Ups J Med Sci Suppl. 1975;19:1-61 
87. Baldassarre D, Nyyssonen K, Rauramaa R, de Faire U, Hamsten A, Smit AJ, 
Mannarino E, Humphries SE, Giral P, Grossi E, Veglia F, Paoletti R, Tremoli 
E. Cross-sectional analysis of baseline data to identify the major determinants 
of carotid intima-media thickness in a European population: the IMPROVE 
study. European heart journal. 2010;31:614-622 
88. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian 
Journal of Statistics. 1979;6:65-70 
89. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 
Homeostasis model assessment: insulin resistance and beta-cell function from 
fasting plasma glucose and insulin concentrations in man. Diabetologia. 
1985;28:412-419 
90. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes 
mellitus provisional report of a WHO consultation. Diabetic medicine : a 
journal of the British Diabetic Association. 1998;15:539-553 
91. Jonsson AS, Flodin M, Hansson LO, Larsson A. Estimated glomerular filtration 
rate (eGFRCystC) from serum cystatin C shows strong agreement with iohexol 
clearance in patients with low GFR. Scand J Clin Lab Invest. 2007;67:801-809 
92. Sundstrom J, Arnlov J, Stolare K, Lind L. Blood pressure-independent relations 
of left ventricular geometry to the metabolic syndrome and insulin resistance: a 
population-based study. Heart. 2008;94:874-878 
   39 
93. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek 
N. Echocardiographic assessment of left ventricular hypertrophy: comparison to 
necropsy findings. Am J Cardiol. 1986;57:450-458 
94. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, 
Alderman MH. Left ventricular mass and body size in normotensive children 
and adults: assessment of allometric relations and impact of overweight. J Am 
Coll Cardiol. 1992;20:1251-1260 
95. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in 
echocardiographic volume determinations: echocardiographic-angiographic 
correlations in the presence of absence of asynergy. Am J Cardiol. 1976;37:7-
11 
96. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, 
Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and 
geometric remodeling in essential hypertension. J Am Coll Cardiol. 
1992;19:1550-1558 
97. Lind L, Andersson J, Ronn M, Gustavsson T. The echogenecity of the intima-
media complex in the common carotid artery is closely related to the 
echogenecity in plaques. Atherosclerosis. 2007;195:411-414 
98. Liang Q, Wendelhag I, Wikstrand J, Gustavsson T. A multiscale dynamic 
programming procedure for boundary detection in ultrasonic artery images. 
IEEE Trans Med Imaging. 2000;19:127-142 
99. Gronholdt ML, Nordestgaard BG, Schroeder TV, Vorstrup S, Sillesen H. 
Ultrasonic echolucent carotid plaques predict future strokes. Circulation. 
2001;104:68-73 
100. Honda O, Sugiyama S, Kugiyama K, Fukushima H, Nakamura S, Koide S, 
Kojima S, Hirai N, Kawano H, Soejima H, Sakamoto T, Yoshimura M, Ogawa 
H. Echolucent carotid plaques predict future coronary events in patients with 
coronary artery disease. J Am Coll Cardiol. 2004;43:1177-1184 
101. Lind L. Arterial compliance influences the measurement of flow-mediated 
vasodilation, but not acetylcholine-mediated forearm blood flow. The 
Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. 
Atherosclerosis. 2007;190:212-215 
102. Ahotupa M, Asankari TJ. Baseline diene conjugation in LDL lipids: an 
indicator of circulating oxidized LDL. Free Radic Biol Med. 1999;27:1141-
1150 
103. Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M. 
Oxidative stress markers in pre-uremic patients. Clin Nephrol. 2001;56:308-314 
104. Fitzgerald SP, Lamont JV, McConnell RI, Benchikh el O. Development of a 
high-throughput automated analyzer using biochip array technology. Clin 
Chem. 2005;51:1165-1176 
105. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller 
J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-
genome association and population-based linkage analyses. American journal of 
human genetics. 2007;81:559-575 
106. Magi R, Kumar A, Morris AP. Assessing the impact of missing genotype data 
in rare variant association analysis. BMC Proc. 2011;5 Suppl 9:S107 
107. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of 
genomewide association scans. Bioinformatics. 2010;26:2190-2191 
108. Marchini J, Howie B. Genotype imputation for genome-wide association 
studies. Nat Rev Genet. 2010;11:499-511 
 40 
109. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
Kondrashov AS, Sunyaev SR. A method and server for predicting damaging 
missense mutations. Nat Methods. 2010;7:248-249 
110. Thomas PD, Kejariwal A, Campbell MJ, Mi H, Diemer K, Guo N, Ladunga I, 
Ulitsky-Lazareva B, Muruganujan A, Rabkin S, Vandergriff JA, Doremieux O. 
PANTHER: a browsable database of gene products organized by biological 
function, using curated protein family and subfamily classification. Nucleic 
Acids Res. 2003;31:334-341 
111. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, 
Sheps D, Keren G, Roth A. Circulating adiponectin concentrations in patients 
with congestive heart failure. Heart. 2006;92:1420-1424 
112. Ingelsson E, Riserus U, Berne C, Frystyk J, Flyvbjerg A, Axelsson T, 
Lundmark P, Zethelius B. Adiponectin and risk of congestive heart failure. 
JAMA. 2006;295:1772-1774 
113. Frankel DS, Vasan RS, D'Agostino RB, Sr., Benjamin EJ, Levy D, Wang TJ, 
Meigs JB. Resistin, adiponectin, and risk of heart failure the framingham 
offspring study. J Am Coll Cardiol. 2009;53:754-762 
114. Beatty AL, Zhang MH, Ku IA, Na B, Schiller NB, Whooley MA. Adiponectin 
is associated with increased mortality and heart failure in patients with stable 
ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis. 
2012;220:587-592 
115. Wannamethee SG, Welsh P, Whincup PH, Sawar N, Thomas MC, Gudnarsson 
V, Sattar N. High adiponectin and increased risk of cardiovascular disease and 
mortality in asymptomatic older men: does NT-proBNP help to explain this 
association? Eur J Cardiovasc Prev Rehabil. 2011;18:65-71 
116. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic 
peptides: a new lipolytic pathway in human adipocytes. FASEB J. 
2000;14:1345-1351 
117. Sengenes C, Bouloumie A, Hauner H, Berlan M, Busse R, Lafontan M, 
Galitzky J. Involvement of a cGMP-dependent pathway in the natriuretic 
peptide-mediated hormone-sensitive lipase phosphorylation in human 
adipocytes. J Biol Chem. 2003;278:48617-48626 
118. Moro C, Crampes F, Sengenes C, De Glisezinski I, Galitzky J, Thalamas C, 
Lafontan M, Berlan M. Atrial natriuretic peptide contributes to physiological 
control of lipid mobilization in humans. FASEB J. 2004;18:908-910 
119. Lavoie F, Frisch F, Brassard P, Normand-Lauziere F, Cyr D, Gagnon R, Drouin 
R, Baillargeon JP, Carpentier AC. Relationship between Total and High 
Molecular Weight Adiponectin Levels and Plasma Nonesterified Fatty Acid 
Tolerance during Enhanced Intravascular Triacylglycerol Lipolysis in Men. J 
Clin Endocrinol Metab. 2009;94:998-1004 
120. Tanaka T, Tsutamoto T, Sakai H, Nishiyama K, Fujii M, Yamamoto T, Horie 
M. Effect of atrial natriuretic peptide on adiponectin in patients with heart 
failure. Eur J Heart Fail. 2008;10:360-366 
121. Tsukamoto O, et al. Natriuretic peptides enhance the production of adiponectin 
in human adipocytes and in patients with chronic heart failure. J Am Coll 
Cardiol. 2009;53:2070-2077 
122. Kintscher U. Does adiponectin resistance exist in chronic heart failure? 
European heart journal. 2007;28:1676-1677 
123. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K, 
Okazaki Y, Ishii T, Nishikai K, Saruta T. Correlation of the adipocyte-derived 
protein adiponectin with insulin resistance index and serum high-density 
   41 
lipoprotein-cholesterol, independent of body mass index, in the Japanese 
population. Clin Sci (Lond). 2002;103:137-142 
124. Vadacca M, Zardi EM, Margiotta D, Rigon A, Cacciapaglia F, Arcarese L, 
Buzzulini F, Amoroso A, Afeltra A. Leptin, adiponectin and vascular stiffness 
parameters in women with systemic lupus erythematosus. Intern Emerg Med. 
2011 
125. Kawamoto R, Tabara Y, Kohara K, Miki T, Kusunoki T, Katho T, Ohtsuka N. 
Serum high molecular weight adiponectin correlates with arterial stiffness in 
community-dwelling persons. Endocr Res. 2011;36:53-63 
126. Kunita E, Yamamoto H, Kitagawa T, Ohashi N, Utsunomiya H, Oka T, 
Horiguchi J, Awai K, Kihara Y. Association between plasma high-molecular-
weight adiponectin and coronary plaque characteristics assessed by computed 
tomography angiography in conditions of visceral adipose accumulation. 
Circulation journal : official journal of the Japanese Circulation Society. 
2012;76:1687-1696 
127. Prahl U, Holdfeldt P, Bergstrom G, Fagerberg B, Hulthe J, Gustavsson T. 
Percentage White: A New Feature for Ultrasound Classification of Plaque 
Echogenicity in Carotid Artery Atherosclerosis. Ultrasound Med Biol. 2009 
128. Marso SP, Mehta SK, Frutkin A, House JA, McCrary JR, Kulkarni KR. Low 
adiponectin levels are associated with atherogenic dyslipidemia and lipid-rich 
plaque in nondiabetic coronary arteries. Diabetes Care. 2008;31:989-994 
129. El-Barghouty NM, Levine T, Ladva S, Flanagan A, Nicolaides A. Histological 
verification of computerised carotid plaque characterisation. Eur J Vasc 
Endovasc Surg. 1996;11:414-416 
130. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 
1995;92:657-671 
131. Andersson J, Sundstrom J, Gustavsson T, Hulthe J, Elmgren A, Zilmer K, 
Zilmer M, Lind L. Echogenecity of the carotid intima-media complex is related 
to cardiovascular risk factors, dyslipidemia, oxidative stress and inflammation: 
the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) 
study. Atherosclerosis. 2009;204:612-618 
132. Wohlin M, Sundstrom J, Andren B, Larsson A, Lind L. An echolucent carotid 
artery intima-media complex is a new and independent predictor of mortality in 
an elderly male cohort. Atherosclerosis. 2009;205:486-491 
133. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N 
Engl J Med. 2005;352:1685-1695 
134. Hulthe J, Hulten LM, Fagerberg B. Low adipocyte-derived plasma protein 
adiponectin concentrations are associated with the metabolic syndrome and 
small dense low-density lipoprotein particles: atherosclerosis and insulin 
resistance study. Metabolism. 2003;52:1612-1614 
135. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin 
concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 
2002;87:2764-2769 
136. Motoshima H, Wu X, Mahadev K, Goldstein BJ. Adiponectin suppresses 
proliferation and superoxide generation and enhances eNOS activity in 
endothelial cells treated with oxidized LDL. Biochem Biophys Res Commun. 
2004;315:264-271 
137. Ouedraogo R, Wu X, Xu SQ, Fuchsel L, Motoshima H, Mahadev K, Hough K, 
Scalia R, Goldstein BJ. Adiponectin suppression of high-glucose-induced 
reactive oxygen species in vascular endothelial cells: evidence for involvement 
of a cAMP signaling pathway. Diabetes. 2006;55:1840-1846 
 42 
138. Ouchi N, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid 
accumulation and class A scavenger receptor expression in human monocyte-
derived macrophages. Circulation. 2001;103:1057-1063 
139. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara 
S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new 
member of the family of soluble defense collagens, negatively regulates the 
growth of myelomonocytic progenitors and the functions of macrophages. 
Blood. 2000;96:1723-1732 
140. Matsuda M, et al. Role of adiponectin in preventing vascular stenosis. The 
missing link of adipo-vascular axis. The Journal of biological chemistry. 
2002;277:37487-37491 
141. Miller NE, La Ville A, Crook D. Direct evidence that reverse cholesterol 
transport is mediated by high-density lipoprotein in rabbit. Nature. 
1985;314:109-111 
142. Matsuura F, et al. Adiponectin accelerates reverse cholesterol transport by 
increasing high density lipoprotein assembly in the liver. Biochem Biophys Res 
Commun. 2007;358:1091-1095 
143. Laurent S, Boutouyrie P, Lacolley P. Structural and genetic bases of arterial 
stiffness. Hypertension. 2005;45:1050-1055 
144. Emoto M, Nishizawa Y, Kawagishi T, Maekawa K, Hiura Y, Kanda H, 
Izumotani K, Shoji T, Ishimura E, Inaba M, Okuno Y, Morii H. Stiffness 
indexes beta of the common carotid and femoral arteries are associated with 
insulin resistance in NIDDM. Diabetes Care. 1998;21:1178-1182 
145. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, 
Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close 
association with insulin resistance and hyperinsulinemia. J Clin Endocrinol 
Metab. 2001;86:1930-1935 
146. Wada T, Kodaira K, Fujishiro K, Maie K, Tsukiyama E, Fukumoto T, Uchida 
T, Yamazaki S. Correlation of ultrasound-measured common carotid artery 
stiffness with pathological findings. Arterioscler Thromb. 1994;14:479-482 
147. Tang H, Sebastian BM, Axhemi A, Chen X, Hillian AD, Jacobsen DW, Nagy 
LE. Ethanol-Induced Oxidative Stress via the CYP2E1 Pathway Disrupts 
Adiponectin Secretion from Adipocytes. Alcohol Clin Exp Res. 2011 
148. Briggs DB, Giron RM, Malinowski PR, Nunez M, Tsao TS. Role of redox 
environment on the oligomerization of higher molecular weight adiponectin. 
BMC Biochem. 2011;12:24 
149. Carazo A, Leon J, Casado J, Gila A, Delgado S, Martin A, Sanjuan L, Caballero 
T, Munoz JA, Quiles R, Ruiz-Extremera A, Alcazar LM, Salmeron J. Hepatic 
Expression of Adiponectin Receptors Increases with Non-alcoholic Fatty Liver 
Disease Progression in Morbid Obesity in Correlation with Glutathione 
Peroxidase 1. Obes Surg. 2011 
150. Plant S, Shand B, Elder P, Scott R. Adiponectin attenuates endothelial 
dysfunction induced by oxidised low-density lipoproteins. Diab Vasc Dis Res. 
2008;5:102-108 
151. Sliman SM, Patel RB, Cruff JP, Kotha SR, Newland CA, Schrader CA, 
Sherwani SI, Gurney TO, Magalang UJ, Parinandi NL. Adiponectin Protects 
Against Hyperoxic Lung Injury and Vascular Leak. Cell Biochem Biophys. 
2011 
152. Liao Y, Xuan W, Zhao J, Bin J, Zhao H, Asakura M, Funahashi T, Takashima 
S, Kitakaze M. Antihypertrophic effects of adiponectin on cardiomyocytes are 
associated with the inhibition of heparin-binding epidermal growth factor 
signaling. Biochem Biophys Res Commun. 2010;393:519-525 
   43 
153. Njajou OT, Kanaya AM, Holvoet P, Connelly S, Strotmeyer ES, Harris TB, 
Cummings SR, Hsueh WC. Association between oxidized LDL, obesity and 
type 2 diabetes in a population-based cohort, the Health, Aging and Body 
Composition Study. Diabetes Metab Res Rev. 2009;25:733-739 
154. Park SH, Kim JY, Lee JH, Park HY. Elevated oxidized low-density lipoprotein 
concentrations in postmenopausal women with the metabolic syndrome. Clin 
Chim Acta. 2011;412:435-440 
155. Makedou K, Kourtis A, Gkiomisi A, Toulis KA, Mouzaki M, Anastasilakis 
AD, Gerou S, Gavana E, Agorastos T. Oxidized low-density lipoprotein and 
adiponectin levels in pregnancy. Gynecol Endocrinol. 2011;27:1070-1073 
156. Kizer JR, Arnold AM, Benkeser D, Ix JH, Djousse L, Zieman SJ, Barzilay JI, 
Tracy RP, Mantzoros CS, Siscovick DS, Mukamal KJ. Total and high-
molecular-weight adiponectin and risk of incident diabetes in older people. 
Diabetes Care. 2012;35:415-423 
157. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma 
adiponectin. Clin Chem Lab Med. 2006;44:1264-1268 
158. Zethelius B, Byberg L, Hales CN, Lithell H, Berne C. Proinsulin is an 
independent predictor of coronary heart disease: Report from a 27-year follow-
up study. Circulation. 2002;105:2153-2158 
159. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: stability in plasma over 
36 hours and within-person variation over 1 year. Clinical chemistry. 
2003;49:650-652 
160. Mente A, Razak F, Blankenberg S, Vuksan V, Davis AD, Miller R, Teo K, 
Gerstein H, Sharma AM, Yusuf S, Anand SS. Ethnic variation in adiponectin 
and leptin levels and their association with adiposity and insulin resistance. 
Diabetes Care. 2010;33:1629-1634 
161. Rasmussen-Torvik LJ, Wassel CL, Ding J, Carr J, Cushman M, Jenny N, 
Allison MA. Associations of body mass index and insulin resistance with leptin, 
adiponectin, and the leptin-to-adiponectin ratio across ethnic groups: the Multi-
Ethnic Study of Atherosclerosis (MESA). Ann Epidemiol. 2012;22:705-709 
162. Otvos L, Jr., Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, 
Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E. 
Design and development of a peptide-based adiponectin receptor agonist for 
cancer treatment. BMC Biotechnol. 2011;11:90 
 
 
